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The present study is intended to contribute to an open debate with a broad range of stakeholders on the potential health impact 
associated with the consumption of GMOs by providing up-to-date opinions of experts in this field. For this purpose, the Joint 
Research Centre has collaborated with international experts and, particularly for Annex I and II, it has closely worked with the 
European Food Safety Authority. The JRC is grateful for the high quality of the input provided by these colleagues.
However, the documents provided here do not necessarily represent the agreed views of the collaborating experts nor do they 
necessarily represent the official position of the European Commission or the European Food Safety Authority on this matter.
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5Addressing the potential health impact of food de-
rived from genetically modified plant and animal 
materials forms the basis of a coherent consumer 
protection policy. Dealing with the possible (posi-
tive and/or negative) impact of genetically modi-
fied (GM) food on human and animal health is the 
subject of intensive research and is closely sur-
veyed by the scientific community and the regula-
tory bodies yet, as in many food related fields, as-
sociated issues are complex and often fraught with 
uncertainties and misconceptions. 
The present study is intended to assess the current 
state of expertise in this field and to define possi-
ble areas of improvement. It aims at offering sub-
stantial material for further discussion with a broad 
range of stakeholders.
The report is the outcome of the project ‘Scientific 
and technical contribution to the development of an 
overall health strategy in the area of GMOs’ carried 
out by the Biotechnology & GMOs Unit of the Insti-
tute for Health and Consumer Protection (Joint Re-
search Centre, JRC), in the frame of study contract 
CT 30249, requested by the European Parliament 
Committee on Industry, Research and Energy.
As from the project proposal presented to and ap-
proved by the European Parliament at the begin-
ning of 2007, the study intended to focus in the first 
instance on the assessment of short, medium and 
long term impact of the health effects in relation 
to consumption of genetically modified organisms 
(GMOs). This part of the study consists of a back-
ground document emphasising the state of current 
knowledge, the areas of possible further improve-
ment and the possible ways in which new scientific 
tools may be applied to complement the ongoing 
safety evaluation work. In addition it contains an 
expert opinion in the format of a report of an inter-
national workshop with experts on assessment and 
monitoring of health effects of GMOs (workshop 
held in Ispra 26-27 November 2007). 
In addition, since the first step in addressing health 
impact is the estimation of exposure to (the various 
sources of) GMOs, and the first step in risk man-
agement is providing assurance that no unauthor-
ised GMOs enter the market, the study involved 
scientific research that led to the development of 
a unique tool to detect and identify any of the ap-
proved and non-approved GMOs known to the JRC, 
and in particular its Community Reference Labora-
tory for GM Food and Feed (CRL-GMFF).
The present document includes the items identified 
as key findings of the activities above. The full 
documents are given in Annexes I-III. 
It is important to note that the analyses and dis-
cussions which have led to the present report have 
concentrated on the current approaches to assess 
the potential health effects of GM food and feed 
products and not on the nature of those effects 
themselves. In such context, there has been agree-
ment to follow the classical risk assessment work 
distinction in pre-market assessment and post-
market monitoring phases.
The work undertaken by the JRC has been firmly 
set in the current regulatory context at the EU level 
notably the 2003 regulations on genetically modi-
fied food and feed and on traceability and labelling 
[Regulation (EC) No 1829/2003 and Regulation (EC) 
No 1830/2003].
The overall results of this study show that:
There is a comprehensive body of knowledge • 
that already adequately addresses current 
food safety issues including those dealing 
with GM products; it is considered by the 
experts as sufficient to assess the safety 
of present GM products.
Developments in biotechnology will re-• 
quire even more sizeable efforts to main-
tain an adequate capacity to deal with 
novel products. 
Such R&D efforts need to be firmly inscribed • 
in an international context.
It is essential that a forum is created where • 
stakeholders meet regularly to share ex-
pertise, to identify areas of improvement, 
to forecast upcoming developments and 
to anticipate needs for scientific and tech-
nical efforts.
1 Presentation of the project and report outline
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62 Overall approaches to assess potential short, 
medium and long term effects in relation  
to consumption of GMOs and products  
derived thereof1
1 Timeline:
 On 5 March a first meeting was held in Parma with EFSA in 
order to agree on how to proceed. The background paper 
has been completed and distributed to invited experts 
by 30 October 2007 and the International Workshop took 
place in Ispra on 26-27 November.
The first part deals with the call of the European 
Parliament pointing for ‘the need for the JRC to coor-
dinate the research with an overall health strategy’ 
and to ‘the need to study possible health threats 
coming from genetically modified organisms such 
as maize MON863’.
In close collaboration with the European 
Food Safety Authority (EFSA), and with its 
scientific panel on GMOs, the JRC has:
Prepared a background document on this • 
issue entitled ‘Discussion paper on over-
all approaches to assess potential short, 
medium and long term effects in relation 
to consumption of Genetically Modified 
Organisms (GMOs) and products derived 
thereof’.
Organised an • ‘International workshop on 
overall approaches to assess and moni-
tor potential short, medium and long term 
effects in relation to consumption of Ge-
netically Modified Organisms (GMOs) and 
products derived thereof’ to discuss the 
definition and possible evolution of tools 
to assess the potential short, medium and 
long term health issues in relation to GMOs 
and to address the possible ways ahead to 
collect further information in this rapidly 
evolving sector.
Prepared a document collating the views • 
of the experts as expressed during the 
workshop.
In addition, the JRC developed a real-time PCR 
based ready-to-use multi-target analytical system 
for the detection of EU authorised and unauthor-
ised GM events.
The ‘Discussion paper on overall approaches to 
assess potential short, medium and long term 
effects in relation to consumption of Genetically 
Modified Organisms (GMOs) and products derived 
thereof ’ provides a review of current approaches 
to address the area of GMO health impact in the 
pre- and post-market assessment context. This pa-
per has been produced by the Joint Research Cen-
tre, in collaboration with RIKILT - Institute of Food 
Safety (NL) and with input from the European Food 
Safety Authority.
The sole aim of this document is to consider a 
number of scientific issues related to human health 
and consumption of genetically modified organisms 
that should serve as a basis for discussions among 
stakeholders and not to present a complete review 
of all pertinent information available. It should not 
be regarded as an official position of the European 
Commission or the Joint Research Centre or the Eu-
ropean Food Safety Authority.
Its key messages are:
No demonstration of any health effect of GM 1. 
food products submitted to the regulatory 
process has been reported so far, yet, little is 
known about the potential long term health 
effects of any food, including novel food.
The safety of a GMO derived product is estab-2. 
lished relative to its conventional counterpart 
and is, therefore, not absolute. Conventional 
food is often evaluated on the base of its his-
tory of safe use.
The assessment of potential toxicity common-3. 
ly includes the search for similarities between 
the primary structure of the protein(s) intro-
duced by genetic modification into the host 
organism and the structures of known toxic 
proteins using bio-informatics methods. In 
addition, the susceptibility of the newly intro-
duced protein to conditions of food and feed 
processing, as well as digestion, can provide 
an indication of the likelihood that the con-
sumer will be exposed to the intact protein. 
Repeated-dose feeding of new proteins in 4. 
a subchronic experiment (e.g. for 28 days), 
are recommended. However, in a number 
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7of dossiers that have already been notified 
for regulatory approval in the EU subchronic 
90-day whole-product feeding studies in ro-
dents (rats) have been provided. Such stud-
ies should not be done on a routine basis, but 
only if there are indications to do so, such as 
substantial differences observed in the com-
positional analysis between the GM and its 
non-GM comparator.
With respect to allergenicity a weight of evi-5. 
dence approach is recommended combining 
the outcome of various assessment methods. 
Various studies published in scientific litera-
ture focus on the possible allergenic effects 
of the market-approved GM crops. Sera bind-
ing or skin reactions have not been observed 
for GM crops that have been allowed onto the 
European market.
Genes of bacterial origin in GM plants may 6. 
theoretically be capable of being taken up by 
bacteria in the food chain. Horizontal gene 
transfer risks have been raised with respect to 
antibiotic resistance genes which may devolve 
to pathogenic micro-organisms thereby impair-
ing antibiotic therapy. However, the chances of 
acquiring the same gene(s) from other bacteri-
al species in the environment rather than from 
GMOs are considered much greater.
Two points are of paramount7.  importance to 
consider possible consequences for human 
and animal safety in the rare cases of uptake 
of DNA from food by mammalian cells. First, 
DNA sequences of various origins (plant, ani-
mal, microbia, and virus) are always present 
in human food and farm animal feed. There-
fore, most sequences to be found in GM crop 
plants will have entered the mammalian gut 
before present time. Second, it is clear that 
uptake is very much more probable for so-
matic cells (particularly those of the gut and 
immune systems) than for germ line cells. 
This may account for the almost complete 
lack of evidence for sequences of plant origin 
in mammalian genomes. Somatic cells of the 
gut lining have a rapid turnover, such that the 
most likely fate of most modified cells is to be 
lost in the faeces. These considerations make 
deleterious consequences improbable.
Unintended effects are those not directly 8. 
linked to the targeted genetic modifications 
(disruption in the natural function of 
genes); this may also occur in conventional 
crop breeding. 
Changes in the nutrient composition of GM 9. 
product may impact on human and animal nu-
trition; in such case in vivo feeding trials may 
be decided depending upon the knowledge 
available on those nutrients. 
GM crops which are metabolically engineered 10. 
to produce nutrients (or other products) of in-
terest are likely to be prone to unintended ef-
fects besides the modification of interest. In 
such case, advanced ‘omics’ technologies can 
be used to identify the substance(s) linked to 
the transformation. Comparison with a con-
ventional counterpart is used, taking into ac-
count natural background variations. General-
ly, it is considered that the routine application 
of these techniques in regulatory risk assess-
ment requires additional harmonisation and 
validation, as well as development of data-
bases for the data on background variation. 
Precaution is the reason for the comprehensive 11. 
pre-market safety assessment and follow-up 
by post-market monitoring currently applied 
to GMOs, in order to reduce the uncertainty 
regarding any potential health effects of GM 
technology to a minimum. Current experience 
with long term testing of GMO carried out in 
the formal regulatory approval context, point 
with an appropriate degree of certainty to the 
absence of potential health effects. The data 
evaluated for submitted GM dossiers do not 
indicate any harm caused by these GMOs.
Most of the multigenerational feeding studies 12. 
performed with laboratory rodents show no 
significant effect on testicular spermatocytes 
(GM soya beans), on fertility (GM potatoes), cell 
ultrastructure (GM soya beans) and only diet-
related changes with GM canola. No uptake of 
transgenic DNA from gastrointestinal tract has 
been observed. Human experiments with GM 
tilapia fish showed no differences in cytologi-
cal and biochemical blood composition.
To examine a number of statements cited in the 
background document, a workshop entitled ‘Over-
all approaches to assess and monitor potential 
short, medium and long term effects in relation to 
consumption of Genetically Modified Organisms 
JRC Reference Reports
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8(GMOs) and products derived thereof ’ (JRC, Ispra, 
26-27 November 2007) was attended by 22 experts 
in different disciplines relevant to pre-assessment 
and post-market evaluation of GMOs and GM de-
rived food and feeds. 
The discussions held during the workshop  
were organised along the following headings: 
general observations• 
pre-market assessment • 
post-market monitoring• 
future developments and research needs.• 
The full workshop report presented in Annex II has 
been reviewed and approved by the participants 
Main findings as regards the pre-authorisation/
pre-market phase
GMOs pre- and post-market assessment ac-1. 
tivities need to be ahead of the technology 
and take proactive instead of reactive ap-
proaches. Regular stakeholder fora should be 
organised to increase confidence in and ef-
fectiveness of the whole risk assessment and 
management process.
Presently, the comparative approach is inter-2. 
nationally recognised as the appropriate prin-
ciple for GMOs safety assessment and guide-
lines have been established by EFSA, WHO, FAO 
and OECD. The comparative safety assessment 
(CSA) is based on the comparison of a GMO 
with an appropriate conventional counterpart 
(the comparator) with a history of safe use; the 
exercise is carried out on a case by case basis. 
This approach is necessary because there is a 
large natural variation within a plant species in 
terms of genetic background and environmen-
tal conditions introducing a variable compara-
tor baseline. The weight of evidence based on 
the currently used toxicological, nutritional, 
molecular, and allergological data require-
ments constitutes a robust frame for the pre-
diction of potential health effects.
Safety assessment of novel food can be more 3. 
demanding than safety assessment of GMOs 
as in some cases a comparator with a history 
of safe use is not available. 
The need for testing for allergenicity – a key 4. 
concern in food safety – is common to GM 
and non-GM food products. Suitable models 
to address allergenicity in food in general are 
still missing.
Much more than in the case of Genetically 5. 
Modified Plants, Genetically Modified Micro-
organisms (GMM) raise the concern for gene 
transfer in the digestive tract. Codex guide-
lines and EFSA guidance document deal with 
safety evaluation procedures in such case.
Possible unintended effects cannot be known 6. 
or defined a priori, but are subject of hazard 
identification and risk assessment. The prob-
ability of occurrence of unintended effects 
is part of the uncertainty analysis in the risk 
procedure per se, in which the aim is to reach 
the highest possible degree of scientific 
certainty.
From a scientific point of view, assessing the 7. 
effect of GM food and derived products is not 
different than assessing safety issues associ-
ated with other types of food such as novel 
food and functional food types (such as those 
producing specific molecules for non-food 
purpose). Safety approaches should be coher-
ent across the spectrum following the princi-
ple that products with similar degrees of risks 
should face similar degrees of scrutiny.
Since zero risk is inexistent (or at least science 8. 
can never prove it), comparative risks analysis 
must be conducted and risk mitigation meas-
ures may be recommended in some cases. 
Health effects can be positive or negative. 9. 
However, benefit analysis is generally not 
part of the current assessment but it may be-
come gradually more addressed.
More complex GM products will have to be 10. 
dealt with in future safety assessment; they 
are those which can introduce unforeseen 
metabolic perturbations. These cases will 
require new tools to identify and character-
ise unforeseen effects besides the intended 
ones. To increase confidence in pre-market 
assessment, it is essential for the scientific 
community involved in such work to be aware 
of new types of GMOs under development 
(plants, micro-organisms and animals).
JRC Reference Reports
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9Main findings as regards the post-market  
monitoring phase
GMO identification methods are essential 1. 
for traceability of GM food and feed through-
out the food chain. Identification methods 
are available for all EU approved GMOs but 
more work needs to be done, for instance on 
the development of more robust sampling 
schemes. It is also noted, that it is not achiev-
able to distinguish stacked events (i.e. the 
combina tion of two or more single events in 
one crop) from mixtures of crops in derived 
products containing the corresponding sin-
gle events with the current analytical means. 
This may effect GM quantification. 
Monitoring is regulated for GM derived food 2. 
and feed products, as well as for cultivated 
GMOs, but may also be necessary in cases 
of contained use (e.g. non-food applications, 
GM micro-organisms) as an additional meas-
ure of impact assessment. 
Case specific monitoring can address uncer-3. 
tainty about exposure to a specific genetic 
modification or potential effects thereof; in 
the European Union, there have been no rea-
sons so far to undertake such action.
However, while no monitoring of GM prod-4. 
ucts for health effects has been necessary 
in the European Union, EFSA is of the opinion 
that for the case of GM functional food (e.g. 
with specific health claim) a monitoring pro-
gramme should be put into place.
As in the pre-market phase, monitoring 5. 
needs of GM food and feed products would 
be similar to those of non-GM products; this 
is particularly the case for food with specific 
health claims.
Addressing the identification of unapproved 6. 
GMOs must be further developed and inter-
national cooperation is essential to progress 
in this context. 
Attention must be given to false negative re-7. 
sults leading to the assumed absence of GM 
products when they are present in reality and 
various recommendations regarding certifica-
tion are made in this respect.
Exposure assessment is central in monitor-8. 
ing; it requires extensive EU consumption 
data which are not generally available. The 
identity of GM products should be unambigu-
ously traceable to facilitate the identification 
of target groups. This also facilitates with-
drawal if necessary.
Main findings as regards future developments  
and research
There is a strong need for keeping up with sci-1. 
entific advances in biotechnology to address 
potential health effects through extensive 
and regular exchange between stakeholders.
The complex traits of future GM plants now 2. 
need to be addressed when assessing health 
effects; the use of a wider range of organisms 
to introduce new traits via gene technology 
will also present new identification and safety 
assessment challenges.
Additional and fundamental research on new 3. 
GM events or variety traits should be conduct-
ed by independent publicly funded research 
institutions. Insights into possible unintend-
ed changes caused by the new modifications 
are to be obtained. Developers, risk asses-
sors and risk managers have to stay alert for 
the various scenarios which may require sup-
plementary data in addition to the commonly 
employed safety tests during pre-market or 
post-market assessments.
Profiling technologies supported by bioinfor-4. 
matics tools and databases containing pro-
files of products generated under different 
environmental conditions and agricultural 
practices need to be further developed.
Expert groups like the one in this study should 5. 
be reconvened with more stakeholders. 
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3 Development of a real-time PCR based ready-to-
use multi-target analytical system for the detection 
of EU authorised and unauthorised GM events3
Whereas many tools are available to perform ana-
lytical tests, the conditions of post-marketing mon-
itoring are very complex. Such monitoring is how-
ever necessary for (1) assessing the potential long 
term environmental impacts of GMOs, as compared 
with conventional crops, and (2) for monitoring of 
possible health effects of genetically modified food 
and feed as compared with conventional food and 
feed. Such actions are required in the context of 
the Commission’s programme on Life Sciences and 
Biotechnology – A strategy for Europe [COM (2002) 
27) as well as in the Commission’s communication 
on the mid-term review of the strategy on Life Sci-
ences and Biotechnology [COM (2007) 175].
In addition, the European market is not a closed 
system and GMOs and derived products from non-
EU countries may enter the European Union. It can 
not be excluded that also unauthorised GMOs, 
such as in the recent cases of Bt10 maize, LL RICE 
601 and Rice63, or unknown GMOs may enter on 
the European market.
All these elements converge on the need of high-
throughput systems for the rapid and cheap screen-
ing of numerous samples allowing monitoring and 
tracing of GMOs, requirements to support the as-
sessment of exposure to GMOs throughout the ag-
ricultural food and feed chain. Through its own re-
search and chairmanship of the European Network 
of GMO Laboratories (ENGL), the JRC deploys, tests 
and implements high-throughput detection sys-
tems for the detection of GMOs (e.g. in the format of 
microchips) and reports here on the design, evalua-
tion, testing and implementation of test strategies 
that are the basis of a decision-making process to 
detect GMOs and to distinguish between approved 
and non-approved GMOs. 
Adequate monitoring and risk management rely on 
technologies that are able to detect the vast major-
ity of approved GMOs as a first step in exposure as-
sessment and of non-approved GMOs as an essen-
tial requirement to safeguard human and animal 
health (and of the environment, an area which is out 
of the context of the current study). Therefore this 
study was complemented with the development of 
an analytical high-throughput system, which is a 
parallel screening tool for the unequivocal simulta-
neous identification and evaluation of the presence 
of all current EU approved and of all unapproved 
GMOs known to the Community Reference Labora-
tory for GM Food and Feed (CRL-GMFF) that may be 
present in food and feed products. 
‘Development of a real-time PCR based ready-
to-use multi-target analytical system for the de-
tection of EU authorised and unauthorised GM 
events’, describes thus the development, testing 
and production of such a system. Further it illus-
trates the rationale and comparative advantage 
of the strategy selected as well as the formula-
tion, potentiality and flexibility of the developed 
analytical system; i.e. on a regular basis a new, 
adapted system that responds to the introduction 
of GMOs in the market can be readily developed. 
However, before applicable for regulatory pur-
poses, extensive testing is still required. There-
fore this tool can only be used for indicative pur-
poses during its first stage. Experimental design 
and testing results are reported in detail, togeth-
er with the timeline followed for the realisation of 
the project, the milestones and deliverables. 
The approach taken allows the event-specific si-
multaneous detection of 39 single-insert GMOs, 
comprising all EU approved and all unapproved GM 
events for which a method was submitted to the 
CRL-GMFF and stacked events derived from them. 
System performance (specificity, efficiency etc) 
has been successfully confirmed by experimen-
tal testing (validation) conducted within the CRL-
GMFF. The project has been already presented to 
members of the ENGL. The ‘real-time PCR based 
ready-to-use multi-target analytical system’ devel-
oped by the JRC, is the first analytical tool devel-
oped worldwide allowing the detection of so many 
GM events simultaneously using event-specific tar-
gets, and it is currently tested in a large variety of 
EU laboratories. Moreover, the use of such a tool 
by laboratories within the EU may guarantee a high 
level of harmonisation.
3 This work has been carried out throughout the year 2007 in 
the JRC laboratories. The final product has been presented 
and discussed at the 9th Plenary Meeting of ENGL where 
members accepted this system with interest and asked 
for the transferability to their laboratories provided they 
would report back on its effectiveness in controlling the 
food and feed market. 
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Annex I
Background paper on overall approaches 
to assess potential short, medium and long 
term effects in relation to consumption 
of Genetically Modified Organisms (GMOs) 
and products derived thereof
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Bt, Bacillus thuringiensis; DNA, deoxyribonucleic acid; EC, European Commission; EFSA, European Food Safety Authority; ENGL, 
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This document has been prepared by the Joint Re-
search Centre (JRC) of the European Commission, 
following its mandate to provide an answer to que-
ries from the European Parliament. These queries 
pertain to the potential health effects of geneti-
cally modified organisms (GMOs) and ways to de-
tect these effects, including the use of advanced 
analytical methodologies. Emphasis is given to the 
data generated in the pre-marketing and post-mar-
keting phases, in particular for the pre-marketing 
risk assessment and/or post-marketing monitoring 
of non-intended health effects. 
A preliminary version of this document has served 
as background information for a workshop on the 
possible short, medium and long term health ef-
fects of genetically modified organisms (GMOs) 
organised by the JRC, in November 2007. The work-
shop addressed various questions on the nature, 
quality, and interpretation of the above-mentioned 
data generated during the pre-marketing and post-
marketing phases. In particular, it was considered 
whether the data generated are sufficient to carry 
out an effective risk assessment and subsequent 
risk management, including post-market monitor-
ing, if applicable.
1.1 Genetically modified food and feed
GMOs, as defined by European legislation (Di-
rective 2001/18/EC), particularly include organ-
isms that have undergone introduction of foreign 
DNA with the aid of recombinant DNA techniques. 
These techniques have enabled the transfer of ge-
netic information between organisms that are not 
amenable to such transfer by natural means. The 
techniques of genetic modification therefore ex-
pand the tools available for genetic improvement 
of crops, animals, and micro-organisms used for 
production of food, medicines, and other non-
food products, as well as for other purposes of 
utility to man.
Since the first large-scale introduction of cultivation 
of genetically modified (GM) crops, the area plant-
ed with these crops has continuously increased, up 
to 102 million hectares in 2006. In addition, most 
of the currently commercialised GM crops are of 
high economic value, including field crops such as 
soybean, maize, cotton, and oilseed rape. Most of 
these crops are cultivated outside the European 
Union (EU), particularly the USA, Argentina, Brazil, 
Canada, China, India. Only one GM maize has also 
been cultivated to some extent in Europe.
The major characteristics that have been intro-
duced into GM crops are herbicide resistance and 
insect resistance. Herbicide resistance allows crops 
to survive the application of particular herbicides, 
thereby facilitating management of weeds growing 
among the crop plants. The most widely grown GM 
crop currently is GM herbicide-resistant soybean, 
which has been rendered resistant against herbi-
cide formulations containing glyphosate, which 
is a ‘broad-spectrum’ herbicide that kills several 
weeds. Insect resistance renders the crop resistant 
against particular pest insects. Many insect-resist-
ant GM crops have been modified with insecticidal 
proteins that naturally occur in the soil bacterium 
Bacillus thuringiensis (Bt), which is also used as a 
natural pesticide in organic agriculture. These pro-
teins are toxic for specific insect species, such as a 
Bt protein toxic to European corn borer.
Besides the characteristics of agricultural impor-
tance that have been introduced into the main 
share of currently cultivated GM crops, crops that 
are currently in development and that may enter the 
market in the future, also contain characteristics of 
potential importance to consumers. A well-known 
example of such a crop is ‘Golden Rice’, which has 
been modified with various enzymes enabling 
the biosynthesis of provitamin A (β-carotene) in 
its kernels. The purpose of this modification is to 
combat malnutrition in various parts of the world 
where rice consumption is high and physiological 
levels of vitamin A are low. In addition, the modi-
fication comprises the introduction of a pathway 
that is not naturally active within rice kernels, and 
therefore is more complex than the modifications 
introduced into the currently commercialised GM 
crops. Other examples include GM crops such as 
soybean with modified oil composition and maize 
with increased levels of the essential amino acid 
lysine that have recently been notified for market 
approval as GM food and feed under Regulation 
(EC) No 1829/2003.
1.2 Pre-market safety assessment
Before GM crops are allowed onto the EU mar-
ket, they have to be granted regulatory approval, 
for which they also have to pass regulatory as-
sessment of their safety. The safety assessment 
is done through a centralised procedure under 
the auspices of the GM food and feed regulation 
[Regulation (EC) No 1829/2003]. In accordance 
with the provisions laid down in this Regula-
tion, the European Food Safety Authority (EFSA) 
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conducts a comprehensive safety assessment. 
Based on this assessment, EFSA publishes an 
opinion to inform the European Commission, the 
EU Member States, and the public about the safe-
ty of the GM product. EFSA’s advice is based on 
opinions issued by its GMO Panel, which consists 
of various experts from the EU Member States 
that have been elected as members based on 
their expertise, experience, and independence. 
In addition, during the regulatory safety assess-
ment procedure, EU Member State authorities 
can provide comments to the dossier contents for 
the attention of the GMO Panel. Below, it will be 
discussed in further detail which data are needed 
to address the various potential health effects 
that are commonly considered during the safety 
assessment of GMOs.
Besides the scientific assessment of safety of 
GMOs, applicants submitting applications for mar-
ket approval of their GM products, also have to 
provide a specific detection method for the perti-
nent GMO. This detection method usually consists 
of polymerase-chain-reaction-based DNA detec-
tion, which can detect DNA that is specific for the 
particular GMO. This method plus control samples 
have to be provided to the Biotechnology & GMOs 
Unit at the JRC, which exercises the role of Commu-
nity Reference Laboratory for GM Food and Feed, 
as mandated in the context of Regulation (EC) No 
1829/2003 (http://gmo-crl.jrc.ec.europa.eu/). The 
CRL-GMFF will validate the method and determine 
if it is suitable for regulatory purposes. This valida-
tion process includes the execution of a ring trial, 
which is done in collaboration with various labora-
tories. These laboratories are all members of the 
European Network of GMO Laboratories (ENGL), 
which is coordinated by JRC. The JRC provides a fi-
nal validation report to EFSA which, together with 
the opinion and other particularities, forms the 
overall opinion according to Regulation (EC) No 
1829/2003 (http://www.efsa.europa.eu).
The overall opinion will serve as input for the de-
cision (authorisation or rejection) to be drafted 
by the European Commission on the market in-
troduction of the particular GMO. This draft will 
be submitted to a regulatory committee, i.e. the 
Standing Committee on the Food Chain and Ani-
mal Health. Depending on the outcome of the 
Standing Committee’s discussions, it may also be 
forwarded to the Council of Ministers, before be-
ing returned to the European Commission for the 
final disposition.
The pre-market assessment of the safety of 
the GMO thus has an important role in the EU 
approval procedure for market authorisation. 
European legislation is put in place so that the 
outcomes of the assessment are used as the 
scientific basis for the decisions by EU institutions 
on the management of risks following the market 
approval of GMOs; no GMO can be put on the 
market unless it receives a positive EFSA opinion. 
This document therefore highlights various issues 
surrounding potential health effects of GMOs, 
including (a) the current practice of pre-market 
assessment of potential health effects, (b) post-
market monitoring for health effects, (c) scientific 
background of the assessment methods, and (d) 
potential needs for further research.
After the GM product has been introduced onto the 
market, there are several regulatory principles put 
in place to follow-up the products released, i.e. the 
post-market phase.
First, each GM product can be released on the mar-
ket only for 10 years. After this period, the appli-
cant must submit again a dossier for renewal of the 
authorisation. This dossier must contain updated 
scientific information and the knowledge gained 
from experience with the concerned GM product 
on the EU market. Based on this dossier, EFSA will 
perform its risk assessment which will be used by 
the EC as the scientific basis for its decision on the 
renewal of the market authorisation of the con-
cerned GMO product.
Second, post-market monitoring and/or other risk 
management measurements of GM products can 
be taken if deemed necessary from a safety or eco-
nomical perspective. These aspects will be further 
discussed in this document. 
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Years before the first large-scale introduction 
of GMOs onto the market, national and interna-
tional organisations discussed what approach for 
safety assessment of such products should be 
undertaken. This involved international organisa-
tions such as Food and Agricultural Organisation 
(FAO), World Health Organisation (WHO), Organi-
sation for Economic Cooperation and Develop-
ment (OECD), and the International Life Sciences 
Institute (ILSI) [Kuiper et al., 2001]. For foods de-
rived from genetically modified organisms, this 
resulted in the publication of the internationally 
harmonised guidelines for the safety assessment 
of foods derived from GM plants and micro-organ-
isms by Codex Alimentarius in 2003. Codex Ali-
mentarius is an international committee resulting 
from a joint collaboration of FAO and WHO, which 
develops protocols and standards for foods. Codex 
documents have to be implemented by each of its 
member states into national legislation because 
they serve as point of reference for international 
trade rules. At Codex meetings, the joint EU mem-
ber states are represented by the European Com-
mission with scientific support from EFSA staff and 
experts. The EFSA GMO Panel has published a de-
tailed guidance document for applicants who wish 
to make a marketing application for GM products. 
This guidance extends the Codex guidelines and 
provides directions on the information needed to 
be included within the safety dossier on the perti-
nent GMO [EFSA, 2006a].
The internationally harmonised approach prom-
ulgated by Codex and accepted by other relevant 
institutions including EFSA, is that of the compara-
tive safety assessment [Kok and Kuiper, 2003]. This 
approach focuses on the differences found in the 
comparison of a GM product with a conventional 
counterpart with a history of safe use. This compari-
son commonly includes an analysis of the molecular 
characteristics, the phenotypic/agronomic char-
acteristics, and many compositional parameters in 
both the GMO and its counterpart. For example, in a 
Bt-protein-expressing GM maize, the difference with 
conventional maize likely includes the presence of 
this new protein. Other differences found may be 
intended or unintended. For any differences thus 
found, it then has to be decided if further testing for 
their safety is needed. In case of a new protein, this 
may entail the testing of its toxicity and allergenic-
ity, for example, of which the data requirements 
and data collection will be further detailed below. 
The comparison of a GMO with its counterpart thus 
serves as a starting point in the safety assessment.
Following the comparative safety assessment ap-
proach, the safety of a GMO is established relative 
to a conventional counterpart, which implicitly pre-
sumes the safety of the latter. This is based on the 
fact that whilst conventional foods usually have not 
been tested for safety, their history of safe use in-
dicates that a positive balance has been found be-
tween the potentially negative and positive effects 
of the many substances present within these foods. 
For example, based on experiences with breed-
ing certain food crops, such as potato and canola 
(oilseed rape for human and animal consumption), 
threshold levels are applied for intrinsic compounds 
known to have adverse effects, i.e. glycoalkaloids in 
potato and erucic acid and glucosinolates in canola.
Items commonly addressed during the safety as-
sessment of GMOs and GM foods and feed in partic-
ular, have been reviewed in more detail previously 
[Kuiper et al., 2001]. For more details the guidance 
document published by EFSA can serve as an exten-
sive resource [EFSA, 2006a]. An overview of these 
items is given in the following sections.
2.1 Molecular characteristics
The molecular characterisation of a GMO includes 
an analysis of the identity, organisation, location(s), 
and genetic stability of the DNA introduced into the 
host organism. In addition, the expression, func-
tion, mode of inheritance of the DNA, and the char-
acteristics and levels of any gene product (e.g. pro-
tein) are analysed.
2.2 Comparative analysis of phenotypic, 
agronomic, and compositional 
characteristics
The comparative analysis entails a comparison of 
phenotypic and agronomic characteristics, includ-
ing ultra-structural and physiological parameters 
(e.g. crop appearance, development, yield, and dis-
ease susceptibility), and an extensive range of com-
positional parameters, including macronutrients, 
micronutrients, antinutrients, toxins, and second-
ary metabolites. Because food organisms can differ 
widely from each other, the exact parameters to be 
measured will vary as well. The OECD Task Force on 
the Safety of Novel Foods and Feed has published 
consensus documents with recommendations for 
key compositional parameters to be analysed in this 
comparison in a range of primary crops, including 
soybean, canola, wheat, maize, barley, rice, potato, 
tomato, cotton, and forage legumes [OECD, 2007].
2 Current approach towards risk assessment of GMOs
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2.3 Potential toxicity
Genetic modification introduces proteins encoded by 
the transgenes into the host. These proteins may not 
be considered truly ‘new’ proteins from the perspec-
tive that they already occur in other naturally occur-
ring organisms, such as the soil bacteria Agrobac-
terium and Bacillus thuringiensis. The assessment 
of potential toxicity commonly includes the search 
for similarities between the primary structure of the 
protein(s) introduced by genetic modification into 
the host organism and the structures of known toxic 
proteins using bio-informatics methods. In addition, 
the susceptibility of the newly introduced protein to 
conditions of food and feed processing, as well as 
digestion, can provide an indication of the likelihood 
that the consumer will be exposed to the intact pro-
tein. A common proxy for digestibility is an in vitro 
simulation model involving incubation of the newly 
introduced protein with simulated gastric fluid. The 
intactness of the new protein during incubation is 
subsequently measured. Additional testing may 
involve the dosing of the newly introduced protein 
to laboratory animals in vivo following established 
protocols for animal testing. The EFSA guidance 
document recommends the repeated-dose feeding 
of new proteins in a subchronic experiment (e.g. for 
28 days), amongst others.
In addition, in a number of dossiers that have al-
ready been notified for regulatory approval in 
the EU and assessed by the EFSA GMO Panel, 
subchronic 90-day whole-product feeding studies 
in rodents (rats) have been provided. EFSA guid-
ance does not recommend that these studies are 
done on a routine basis, but only if there are indi-
cations to do so, such as substantial differences 
observed in the compositional analysis between 
the GM and its non-GM comparator. The scientific 
basis on which this approach has been based is 
explained in further detail by the EFSA guidance 
document and by the recently adopted report on 
the role of animal feeding trials in the assessment 
of the safety and nutrition of food and feed de-
rived from GM plants [EFSA, 2007]. This approach 
is also endorsed by the majority of national risk 
assessors convened during the special GMO 
meeting of the EFSA Advisory Forum in November 
20071. Whole-product testing has its limitations 
based on the fact that foods and feeds are com-
plex mixtures. Unlike pure chemical compounds 
1 See http://www.efsa.europa.eu/EFSA/efsa_
locale-1178620753812_1178656904823.htm
that can be added to animal diets, for example, 
whole foods cannot be tested in a wide dose 
range because of nutritional balance, palatability, 
and bulkiness, among other things. Interestingly, 
the authors of various rat feeding studies carried 
out with GM rice in the frame of the EU-funded 
SAFOTEST project recommend refinements of the 
90-day protocol for testing GM products. These re-
finements include a consideration of the outcomes 
of the repeated-dose feeding studies with the pu-
rified protein, for example to establish safe doses 
in the 90-day study with the whole product. In ad-
dition, these authors recommended including an 
additional non-GM diet that has been spiked with 
the transgenic protein, so that effects due to this 
protein and other components of the GM diet can 
be distinguished. Besides the assays required by 
the internationally harmonised OECD protocol for 
testing chemicals in animals, these authors have 
also carried out additional assays, such as the 
profile of the intestinal microflora [Poulsen et al., 
2007]. Another general development that may fur-
ther enhance the predictive capability of this kind 
of animal trial is ‘toxicogenomics,’ i.e. the meas-
urement of changes in expression of toxicological-
ly relevant genes in animals before clinical effects 
manifest themselves.
Any relevant effect noted in the 90-day feeding 
study may trigger further testing, such as chronic 
feeding studies [EFSA, 2006a; EFSA, 2007]. Con-
versely, if no effects are observed, it will be doubt-
ful if longer-term testing will be able to detect any 
effects. Furthermore, longer-term testing may also 
conceal shorter-term effects due to adaptation of 
the animals.
2.4 Potential allergenicity
Allergenicity is the capacity to be an ‘allergen,’ i.e. 
a substance that is able to elicit allergy, which is 
a hypersensitive immune reaction. Various types 
of allergy exist, including respiratory, contact, 
and food allergies. All known food allergens are 
proteins and therefore the question of whether a 
newly expressed protein could become a poten-
tial food allergen is considered during the pre-
market assessment of GMOs. Codex recommends 
a ‘weight of evidence’ approach, combining the 
outcomes of various methods used for assess-
ment of potential allergenicity, which is also re-
flected within the recommendations made by the 
EFSA guidance document [Codex Alimentarius, 
2003; EFSA, 2006a].
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For example, the source organism of the gene for 
the newly expressed protein is considered, i.e. is 
the source an allergen in its own right. In addition, 
bioinformatics and digestibility analyses similar to 
those for toxicity are commonly carried out. The bi-
oinformatics test outcomes can provide insight into 
similarities between the newly expressed protein 
and allergens, including the presence of antibody-
binding sites in the new protein that may be recog-
nised by sera against a known allergen.
The in vitro digestibility of the newly expressed 
protein additionally provides an indication of the 
likelihood that the newly expressed protein may 
survive digestion and reach the mucosa of the gas-
trointestinal tract, where it may prime the immune 
system for allergic reactions towards the protein 
during subsequent exposure. In case of positive 
findings, sera binding tests are carried out with 
sera from patients known to suffer from allergy to-
wards the pertinent allergen with which the newly 
expressed protein may cross-react.
Therefore, these tests primarily focus on the po-
tential cross-reactivity of a newly expressed pro-
tein with existing allergens and to some degree 
also on its potential to ‘sensitise’ itself, i.e. to 
prime the immune system to respond with allergic 
reactions to itself.
In summary, the ‘weight of evidence’ approach 
combines the outcomes of various tests, including 
a consideration of the history of allergenicity of the 
source of the transgene and of the host organism; 
in silico bioinformatics comparisons of the trans-
genic protein with known allergens; and the in vitro 
digestibility of the transgenic protein in simulated 
gastric fluid. In case of a positive outcome indicat-
ing potential cross-reactivity with known allergens, 
sera-binding tests with sera from patients allergic 
to the specific allergens are recommended.
Various examples exist of indications from these 
experiments that have triggered further testing. 
For example, an experimental GM soybean contain-
ing a transgenic methionine-rich protein from Brazil 
nut has previously been developed with the aim of 
imparting improved nutritional value to these soy-
beans. Because Brazil nut is an allergen, this soy-
bean has been tested for potential cross-reactivity 
in patients allergic to this nut. It has thus been ob-
served that the GM soybean, in contrast to non-GM 
soybean, indeed shows cross-reactivity with Brazil 
nut [Nordlee et al., 1996]. Therefore the responsible 
company has halted its further development and 
this GM soybean has not been commercialised.
Another example is the Starlink™ maize, which 
contains the transgenic Cry9C protein. This 
protein has been rendered more stable towards 
digestion due to an amino acid mutation in its 
primary structure. A scientific advisory panel of 
the American Environmental Protection Agency 
has therefore considered that it has a medium 
likelihood of becoming an allergen. Following 
accidental commingling with food while it was still 
being allowed to be marketed as a feed in the USA, 
the company has initiated a major recall action 
and has withdrawn this from the American market 
[reviewed by Bucchini and Goldman, 2003].
With regard to measuring allergies post-market in a 
population, the French allergovigilance network has 
recently carried out a baseline measurement for fu-
ture monitoring for respiratory allergies towards GM 
insect-resistant maize. This maize is currently being 
grown in some parts of France [Moneret-Vautrin, 
2006]. Also for this kind of research, it will be impor-
tant to be able to establish the GM nature of maize 
plants implicated in reported cases of allergy.
As noted above, EFSA’s recommendations for the 
EU pre-market assessment of potential allergenic-
ity of GMOs is in line with the international Codex 
Alimentarius guidelines.
2.5 Horizontal gene transfer
Various mechanisms exist for the ‘horizontal’ ex-
change of genetic material between non-related 
organisms. This is particularly the case for micro-
organisms, where such transfer can take place 
through events such as plasmid transfer during 
conjugation and transfection by bacteriophages. 
Another mechanism, which is also possible for 
DNA transfer between organisms other than micro-
organisms, is transformation with free DNA. This 
entails the uptake of DNA and subsequently its in-
corporation into the host genome or as a self-repli-
cating element, as well as its stable maintenance. 
The latter, which is the most relevant scenario for 
horizontal gene transfer from GM plants to micro-
organisms, is a rare event as it requires several con-
ditions to be fulfilled. 
The issue of horizontal gene transfer has been 
viewed so far with particular focus on antibiotic re-
sistance genes. Besides their natural presence in 
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micro-organisms, several of these antibiotic resist-
ance genes are also used in genetic modification as 
markers for selection of successfully transformed 
organisms in the initial steps of creation of the ge-
netically modified host organism. These antibiotic 
resistance marker genes therefore do not serve any 
specific purpose in the final product. The assess-
ment focuses on the likelihood that these genes 
may be transferred horizontally, particularly to 
disease-causing (pathogenic) micro-organisms. 
Such a transfer, if successful, may impair the antibi-
otic therapy of these pathogens with the particular 
antibiotic to which these genes confer resistance. 
Items considered during the assessment therefore 
also include the clinical importance of the pertinent 
antibiotic substance and the background level of 
naturally developed resistance towards the antibi-
otic [for a review see Van den Eede et al., 2004].
Directive 2001/18/EC on the environmental release 
of GMOs states that particular consideration should 
be paid in the environmental risk assessment to 
GMOs containing antibiotic resistance genes in or-
der to phase out any antibiotic resistance genes that 
may have an adverse effect on human health and/
or the environment. Recognising the need for guid-
ance on this issue, the EFSA GMO Panel proposed 
to classify antibiotic resistance marker genes into 
three categories, i.e. i) genes for which there is no 
rationale to restrict or prohibit their use; ii) genes 
that should be restricted to field trial purposes and 
not be used in GM plants to be commercialised; and 
iii) genes that should not be present in GM plants 
to be commercialised or used in field trials [EFSA, 
2004]. The kanamycin resistance gene nptII, for ex-
ample, falls within the first category of genes that 
could be used in commercialised crops. A recent ex-
ample of a GM crop containing the nptII antibiotic re-
sistance marker gene that has been assessed for its 
safety by the EFSA GMO Panel is a GM starch potato 
(EH92-527-1) with altered starch composition. The 
Panel has concluded that the presence of nptII does 
not pose a risk to human, animal or environmental 
health because of the limited use of the target an-
tibiotics, the widespread background presence of 
this gene in bacteria, and the low likelihood of its 
horizontal transfer from GM plants to bacterial re-
cipients [EFSA, 2006b].
As described above, the potential horizontal trans-
fer of antibiotic resistance genes is one of the is-
sues that is commonly considered during the pre-
market assessment of GM crops. Because this 
transfer has only been observed under particular 
conditions, such as the presence of highly homolo-
gous sequences in the recipient organism and the 
need for transfer of intact sequences, the avoid-
ance of the use of certain antibiotic resistance 
genes can be regarded as a precautionary ap-
proach. The trigger for this assessment therefore 
is the presence of antibiotic resistance genes in 
the GMO under consideration.
From a broader perspective, the question can be 
raised as to whether the transfer of transgenes in-
troduced into GMOs to other organisms can have an 
impact on the health of consumers. For example, be-
sides antibiotic resistance, questions pertaining to 
the selective advantage conferred to the recipient 
organism and other factors influencing pathogenic-
ity can be raised as well [e.g. Kleter et al., 2005]. 
These considerations, which are primarily based 
on non-experimental data, are commonly part of 
the environmental risk assessment of GMOs as car-
ried out under Directive 2001/18/EC. With regard 
to the transfer of transgenes to intestinal micro-or-
ganisms, Netherwood and co-workers [2004] have 
found indications of such a transfer of the cp4 epsps 
gene from soy ingested only by ileostomy patients 
having an incomplete digestion, but have been un-
able to further substantiate this finding or demon-
strate it in healthy individuals where the ingested 
soy is completely digested. 
Another issue is the potential transfer of fragments 
of digested DNA to tissues of animals and/or hu-
mans consuming the food, which can occur equally 
in the case of non-transgenic or transgenic DNA de-
rived from non-GM food or GM food. Particularly in 
domestic animals, experiments have been carried 
out on the survival of DNA of GM crops during diges-
tion and their potential uptake into animal tissues 
and fluids [reviewed by Alexander et al., 2007].
The methodology available includes a consideration 
of the transgenic DNA based on current knowledge 
of factors facilitating gene transfer (e.g. recombina-
tion, self-replicating elements etc) and influencing 
pathogenicity (virulence-associated characteris-
tics, selective advantage, background presence of 
gene). Horizontal transfer experiments have been 
carried out by scientists, both under laboratory con-
ditions (e.g. transfer to micro-organisms) and in vivo 
conditions (detection of transgenic DNA in domestic 
animals). Whilst the uptake of plant DNA fragments 
into animal tissues is a normal biological process 
observed in many experiments, only in some cases, 
transfer to animal tissues has been observed also 
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for transgenic DNA fragments, due to the low level 
of presence of transgenes in the GM food.
The performance of the above type of experiments 
is driven by a ‘low probability, high impact’ sce-
nario, particularly for antibiotic resistance genes. In 
addition, the above research activities should also 
be viewed against the wider background of devel-
opment antibiotic resistance, which is associated 
with the intensive use of certain antibiotics in ani-
mal husbandry and in medicine.
2.6 Unintended effects
Besides the effects targeted by the genetic modi-
fication, such as the introduction of a protein of in-
terest into the GMO, it can be envisaged that also 
unintended effects take place. For example, in the 
hypothetical case that the new DNA has been intro-
duced into a native gene, the function of this gene 
may be disrupted. Unintended effects are not limited 
to the technique of genetic modification, but are also 
known to occur during conventional crop breeding.
One example is the altered glycoalkaloid content in 
GM and conventionally bred potatoes [Kuiper et al., 
2001]. Another example in which metabolic engineer-
ing has led to unexpected effects is Golden Rice. The 
modification of this rice has comprised the introduc-
tion of a pathway leading to beta-carotene biosyn-
thesis. Because beta-carotene does not naturally 
occur in rice kernels, various enzymes have been 
introduced in order to convert part of a common pre-
cursor, i.e. geranylgeranyl pyrophosphate, into beta-
carotene. However, it has been noted that also in the 
absence of one of the transgenic enzymes, GM rice 
kernels are still able to synthesise beta-carotene, 
as well as some other carotenoids that are not the 
target of modification [Ye et al., 2000]. It is therefore 
assumed that the absence of beta-carotene from 
kernels is caused by abolishment of a specific step 
in its biosynthesis, but that the rest of this pathway 
still has been present in a latent form.
The extensive comparative analysis of a GMO and 
its counterpart for phenotypic, agronomic, and 
compositional characteristics can provide indica-
tions of the occurrence of unintended effects in 
the GMO. This will be in the form of differences in 
characteristics that are not directly linked to the tar-
geted effects of genetic modification. In addition, 
the knowledge about the characteristics of the in-
troduced DNA and gene products obtained through 
molecular characterisation of the GMO can also 
provide for the prediction of unintended effects and 
guide further analysis for the verification thereof.
As described above, methods currently available 
to measure any unintended and/or unexpected 
effects include a wide array of compositional, 
phenotypic and agronomic characteristics that 
are measured in a targeted fashion as part of the 
comparative assessment of a GM crop and its con-
ventional counterpart. Additional analysis can be 
performed on the levels of compounds likely to 
be affected by the introduced metabolic modifi-
cations, as it has been done with carotenoids in 
Golden Rice. If considered appropriate for risk 
assessment, also less specific profiling methods 
may be employed to test for differences in GM 
crops with complicated modifications. In addition, 
whole-product feeding studies in laboratory ani-
mals, such as the 90-day rat feeding study, may 
provide additional data on the safety of a crop. It 
should be kept in mind though that differences do 
not necessarily constitute health hazards.
The issue of the choice of the appropriate compara-
tor has an important place in the comparative safe-
ty assessment, which is also why, for example, the 
EFSA GMO Panel pays a lot of attention to this issue 
in its safety assessments of GMO applications, in-
cluding a consideration of breeding pedigree of GM 
crops and their controls. A potential point of con-
sideration may be that in the case of extensively 
modified GMOs, other comparators besides the 
host of the modification can be used for the com-
parison of compositional parameters (e.g. borage 
oil for oil from GM canola containing high levels of 
GLA, as described above). 
2.7 Nutritional value
The compositional analysis of the GMO can also 
highlight changes in its nutrient composition that 
may impact the role of the GMO to human and ani-
mal nutrition. Besides changes in the level of nu-
trients or antinutrients, it can also be envisaged 
that their bio-availability during digestion can be 
altered, such as through a change in matrix or by 
the introduction of enzymes facilitating intestinal 
uptake. If the nutrient composition or availability 
has indeed been changed by the genetic modifica-
tion, in vivo feeding trials may be decided for on a 
case-by-case basis, depending on the knowledge 
already available on these nutrients. Such feeding 
trials may include performance experiments, i.e. 
by measurement of consumption and growth, and 
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balance experiments, to measure bio-availability 
of a nutrient. Because of the differences in nutri-
ent metabolism and requirements of humans and 
animals, appropriate models may differ depending 
upon the target animal and the affected nutrient.
Many application dossiers on GMOs contain chick-
en broiler feeding studies, in spite of the absence 
of any relevant changes in the nutrient composi-
tion. The chicken is a rapidly growing animal reach-
ing full size within six weeks. It is therefore likely 
to show effects in case of nutritional differences 
between the tested diets fed to different groups 
of chicken, including diets containing the GMO and 
those containing its conventional counterpart.
2.8 Potential triggers for follow-up research  
into health effects of GMOs
Various factors that may come up during the pre-
marketing and post-marketing phases are dis-
cussed below as they can be envisaged to trigger 
further research into the potential health effects. 
This is in line with the case-by-case nature of the 
comparative safety assessment approach accord-
ing to the internationally harmonised guidelines 
followed by EFSA and other institutions.
2.8.1 Hazards identified during pre-market  
risk assessment
In this scenario, the pre-market assessment 
indicates that the GMO may contain particular 
hazards that need additional experiments for 
the assessment to be complete. For example, if 
a newly expressed protein shows specific toxic 
effects in a 28-day repeated-dose feeding trial, 
then further toxicity testing may be warranted, 
as recommended by EFSA guidance, such as 
subchronic testing or tests for specific toxic 
effects (e.g. neurotoxicity), if applicable. The same 
also holds true for non-protein substances that 
have been introduced or whose levels have been 
changed, for example as an unintended result of 
the genetic modification. Besides toxic effects of 
a substance observed in toxicity tests, also other 
indications for its potentially toxic properties may 
exist, such as data on this or similar substances 
from literature, databases, or computer-aided 
predictions. These existing data may in certain 
circumstances have to be complemented with 
the outcomes of further toxicity testing to enable 
a conclusion on the toxicity of the introduced or 
altered substance. It can be envisaged, though, 
that the identification of such a hazard during the 
pre-commercial development stage of a GMO may 
already be a reason for its developer to abrogate 
further development. It can be envisaged that ‘food-
grade’ substances are less likely to raise concerns 
over their potential toxicity than certain non-food 
products. A dedicated working group of the EFSA 
GMO Panel is currently preparing recommendations 
complementing the current guidance document on 
the issues surrounding the use of GM food crops 
for the production of non-food/feed substances, 
including medicinal and industrial products.
2.8.2 Uncertainty in the current pre-market  
risk assessment
Various factors can be envisaged that may contrib-
ute to uncertainty over the possible occurrence of 
health effects caused by GMOs. Examples of this 
include the absence of a comparator with a history 
of safe use for the comparative assessment (e.g. in 
case of extensive modifications), the extrapolation 
from laboratory-scale to real-life dimensions, the 
use of animal models for humans, and the potential 
interactions between components from different 
foods. These scenarios do not pertain to GM prod-
ucts per se, but are applicable to any conventional 
product. So far, the data evaluated for GMO dossi-
ers appear to have provided at least an acceptable 
degree of certainty of no harm and therefore little 
uncertainty. The level of uncertainty is an impor-
tant factor for risk managers and may trigger the 
application of the precautionary principle. In fact, 
precaution is also the reason for the comprehen-
sive pre-market safety assessment and follow-up 
by post-market monitoring currently applied to 
GMOs, in order to reduce the uncertainty regarding 
any potential health effects of GM technology to a 
minimum. It should be borne in mind that the pre-
market safety assessment has to reach its conclu-
sion within a reasonable timeframe based on suf-
ficient conclusive evidence according to the state of 
the art tools and technologies.
2.8.3 Post-market verification of assumptions 
made during the pre-market risk assessment
Particularly assumptions about the food intake or 
other ways of exposure of consumers through the 
introduction of a new product may require post-
market verification. This is because the estimated 
exposure and the characteristics of the hazard to-
gether are used as inputs for the risk characterisa-
tion, i.e. an estimation of the likelihood that certain 
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hazards will occur. This has already been practiced 
with various novel foods permitted under Novel 
Food Regulation (EC) No 258/97, such as phyto-
sterol-containing products, of which the intake by 
various consumer groups has been gauged by the 
applicant after the market introduction. Accord-
ing to the internationally harmonised principles of 
food risk assessment, exposure assessment is an 
important part of the risk characterisation proc-
ess and enables the provision of a quantitative risk 
estimate indicating the likelihood that an adverse 
effect associated with the presence of a given haz-
ard in a food will indeed occur by its consumption. 
Other kinds of pre-market assumptions besides 
intake estimates can also be verified, such as, for 
example, the physiological levels of fat-soluble vi-
tamins in consumers eating products containing fat 
substitutes that also may reduce the uptake of such 
vitamins from the diet.
In a hypothetical scenario, if substantive differenc-
es between the pre-market estimate and the post-
market measurement occur, the risk assessment 
and risk management of the pertinent product 
may have to be revisited. The same also pertains 
to any unexpected effects of a marketed product 
reported through surveillance systems that non-
discriminately record any type of effect, contrary to 
hypothesis-driven monitoring. In all these cases, 
the risk assessment has to be adjusted and further 
investigations may be prompted into the details of 
the mechanisms underlying these differences. It is 
important to keep in mind that science evolves over 
time, and may give rise to new pertinent informa-
tion, which, however, does not specifically apply to 
modern biotechnology alone.
2.9 Current approaches for  
post-market monitoring
From a general perspective, article 5 of Regula-
tion (EC) No 1829/2003 requires that a post-market 
monitoring plan is submitted, as appropriate for the 
use of food and feed. In addition, it can be envis-
aged that the monitoring will be facilitated by the 
labelling and traceability of GMO-containing foods 
as required by Regulation (EC) No 1830/2003. The 
applications that have been subject of EFSA opin-
ions so far have contained environmental monitor-
ing plans, but not monitoring plans for food and 
feed safety, though, based on the fact that no risks 
have been identified in the risk assessment that 
would require such follow-up monitoring. Monitor-
ing plans that have been provided so far pertain to 
the environmental risks of GM crops, including the 
potential for insect resistance in crops expressing 
insecticidal proteins originating from Bacillus thur-
ingiensis. In this context for environmental moni-
toring, a distinction is made between case-specific 
monitoring and general surveillance, being two 
distinct requirements under different conditions as 
part of the post-market monitoring plan.
In addition, applicants have provided general sur-
veillance plans for unanticipated environmental 
effects, as part of the requirements of Directive 
2001/18/EC on the environmental release of GMOs. 
These surveillance plans also include potential ef-
fects arising from animal feed use. These plans 
preferably should draw upon existing networks and 
because of their general nature, there is no specific 
experimental methodology, yet the statistical valid-
ity is important [Bartsch et al., 2006]. The surveil-
lance activities entail the interrogation of farmers 
through questionnaires, as well as the collection of 
information from existing networks of profession-
als, including veterinarians, feed processors, etc.
The Food Standards Agency (FSA) has previously 
commissioned research into the feasibility of the 
use of consumption data from household food pur-
chase surveys and supermarket loyalty cards for 
post-market monitoring of health effects related 
to consumption of GM foods [Elliott et al., 2003]. It 
has thus been observed that the household food 
purchase data are able to cover approximately 70% 
of the actual consumption of these households. 
In addition, data have been striated into various 
geographical regions of the UK, as well as socio-
economic classes. Based on the results, FSA rec-
ommends further refinements to the collection of 
household food purchase data, as well as the link-
age to health statistics of the national health sys-
tem [Elliott et al., 2003].
Various potential drivers for post-market monitor-
ing of GM foods are considered by Hlywka and co-
workers [Hlywka et al., 2003], i.e. the potential for 
allergenicity, potential chronic health effects, con-
firmation of pre-market exposure estimates, and 
identification of changes in food intake or dietary 
habits. These authors also note that demonstration 
of causality, i.e. the link between a health effect and 
exposure to a given food, is important. This may 
entail the use of quantitative exposure assessment 
methods, including probabilistic methods, which 
also are able to discern between various consumer 
subgroups [Hlywka et al., 2003].
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In addition, the Canadian Biotechnology Advisory 
Committee has previously considered the possibil-
ity for post-market surveillance and monitoring of 
GM foods. Their recommendations have particu-
larly focused on the potential allergenicity of these 
foods, given the lack of a suitable validated animal 
model [CBAC, 2002].
2.10 Outlook 
The current approach towards the comparative 
analysis of the characteristics of a GMO and its 
conventional counterpart involves the analysis 
of an extensive dataset. This has been applied 
satisfactorily to the assessment of GM crops with 
modifications that are relatively minor, such as 
the introduction of proteins at low levels with no 
conspicuous impact on crop composition. It is 
expected that future crops will also include GM 
crops with more profound changes, such as in crops 
‘metabolically engineered’ with new metabolic 
pathways in order to produce a nutrient of interest. 
These modifications are likely to be more prone to 
the occurrence of unintended effects besides the 
modification of interest.
Various European initiatives, such as those funded 
by the European Commission’s Directorate-General 
for Research and the United Kingdom’s (UK) Food 
Standards Agency (FSA), have tested the applica-
bility and suitability of advanced analytical ‘omics’ 
technologies for the analysis of unintended effects 
in GM crops. These initiatives include, among oth-
ers, the EU-sponsored projects GMOCARE and SAFE 
FOODS (Work Package 1).
Various ‘omics’ technologies are available, 
which provide ‘holistic’ impressions of the 
composition of an organism at various levels 
of cellular organisation. These levels include 
gene expression by measuring the various 
forms of messenger RNA (‘transcriptomics’); the 
occurrence of the various proteins present within 
a sample (‘proteomics’); as well as the various 
metabolites, i.e. chemical compounds formed by 
metabolism present within a biological sample 
(‘metabolomics’). These methods are non-
discriminatory in that the identity of substances 
linked with signals need not be known of 
beforehand. If the comparison between the 
‘omics’ analysis of a GMO and its conventional 
counterpart show differences in a particular 
signal, this ideally will be traced back to the 
substance linked with that signal.
Any difference found should also be offset against 
the natural background variation for the particular 
parameter. For example, Lehesranta has observed 
in a proteomics experiment comparing a GM potato 
with a conventional potato that 9 out of 730 proteins 
occur at different levels in the GM lines. However, a 
comparison between non-GM genotypes, including 
also wild-type potato and a natural relative, has 
shown that 1,077 out of 1,111 proteins occur at dif-
ferent levels, whilst 600 additional spots do occur 
in particular, but not all, genotypes [Lehesranta et 
al., 2005]. Various databases are currently being 
developed with the aim of providing useful back-
ground ranges for crop composition. An example is 
the MoTo DB database for the chemical metabolite 
composition of tomatoes analysed by liquid chro-
matography (LC) coupled to mass spectrometry 
(MS). In order to make chromatograms comparable, 
specific software is used to align peaks from dif-
ferent LC chromatograms and to calculate masses 
belonging to MS peaks. Using this method, various 
previously unknown metabolites have been discov-
ered in conventional tomato [Moco et al., 2006].
The potential of ‘omics’ technologies for application 
in risk assessment of GMOs have been reviewed 
elsewhere in more depth [e.g. Chassy et al., 2004; 
Kok et al., 2003; Kuiper et al., 2003; Shewry et al., 
2007]. Generally, it is considered that the routine 
application of these techniques in regulatory risk 
assessment requires additional harmonisation and 
validation, as well as development of databases 
for the data on background variation. These tech-
niques may nonetheless provide utility in the de-
velopment phase for GM crops with complicated 
modifications as a sentinel for effects on the crop 
composition that warrant further testing. ‘Omics’ 
techniques can be a valuable addition, rather than 
a replacement, of the currently applied targeted 
analysis. In addition, a more targeted fashion of 
‘omics’ can be envisaged if specific metabolic path-
ways are affected (e.g. carotenoid profiling in GM 
crops with altered carotenoid biosynthesis).
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As described in more detail above, the tests that 
have to be carried out within the legal framework 
of regulatory approval for GMOs include an array of 
in vitro, in silico, and in vivo experiments. It should 
be noted that the decision for the type of tests that 
should be required for the safety assessment is 
made and adjusted for each specific GM product, 
taking into account the various types of genetic 
modifications, host organisms, and differences 
found in the comparative analysis. Various dossi-
ers include, for example, results from subchronic 
animal trials with the whole product. These data 
have provided an appropriate degree of certainty 
regarding the absence of potential health effects.
Various reports in scientific literature also give 
an account of clinical and longer-term tests with 
GMOs, which are discussed in more detail below.
3.1 Animal testing
Animals used in testing the safety of GMOs include 
both laboratory rodents and domestic animals. 
Various types of tests that are provided with dos-
siers and that span much or all of the lifetime of 
an animal, such as nutritional studies in chicken 
broiler or swine, are not discussed here. The focus 
therefore is on studies that are not commonly in-
cluded with dossiers.
3.1.1 Laboratory animal testing
Various multigenerational studies have been per-
formed with laboratory rodents, as described in 
more detail below.
Glyphosate-tolerant soybeans have been tested in 
a multigenerational study in which each generation 
of mice received diets containing these soybeans 
(21.35%) or a conventional counterpart. Three gen-
erations of mice have been tested for possible ef-
fects on general health, litter size, and testicular 
spermatocytes of mice of each generation. Except 
for a difference in spermatocyte populations at one 
time point (age 26 days), which is considered to be 
prone to variability, differences have neither been 
observed for spermatocytes at other time points nor 
for other parameters [Brake and Evenson, 2004].
A multigenerational experiment with the same 
setup has been performed on GM insect-resistant 
Bt maize. The outcomes are similar to those of the 
experiment with glyphosate-resistant soybeans 
described above [Brake et al., 2004].
Other multigenerational experiments have also 
been performed with experimental GM canola and 
potato. The GM canola has been modified so that 
it contains a high level of γ-linolenic acid (GLA). 
Diets containing oil from this GM canola and from 
non-GM borage oil (similar GLA content), plus an 
additional control diet without GLA have been fed 
to diets of maternal mice. The litter size and vari-
ous characteristics of the offspring, including be-
havioural and neurotoxicity tests, body weight, 
brain weight and fatty acid composition, have been 
measured. The results show some differences be-
tween the GM canola oil and borage oil groups, 
including decreased body weight and altered brain 
lipid composition. The authors postulate that this 
may relate to the different forms in which GLA oc-
curs in both oils, causing differences in its diges-
tion and metabolism [Wainwright et al., 2003].
The experimental GM herbicide-resistant potato 
has been fed to rats during five generations. 
Besides measurement of body weight and 
feed intake, animals have also been tested 
for reproductive parameters (mating, fertility, 
gestation, spermatocyte motility), offspring 
characteristics (litter size, pup gender ratio, 
viability, development), skeletal and visceral 
deformations, gross necropsy, organ weights 
and histopathology. In addition, organs have 
been checked for the presence of transgenic DNA. 
Besides a difference in fertility in the founder (F0) 
population fed GM potato, which is still within the 
range of control animals, no other effects have 
been observed [Rhee et al., 2005].
A group of researchers has also published various 
studies on the ultrastructure of cells of various or-
gans (liver, spleen, testes) of mice fed glyphosate-
resistant soybean for up to eight months [Vecchio 
et al., 2004, and references therein]. Whilst these 
authors note that the nucleus and other organelles 
may show changes depending on the diet, the cause 
of these changes has not been established. In addi-
tion, the origin of the GM soybean is not specified 
in detail and the model employed is not routinely 
used in toxicity testing.
3.1.2 Domestic animals
A multigenerational feeding trial has been per-
formed in quails [Flachowsky et al., 2005]. Both 
male and female quails have been fed diets con-
taining either insect-resistant GM Bt maize or non-
GM maize. Hen eggs laid after 12 weeks have been 
3 Experience with additional clinical and long term 
testing of GMOs
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used to obtain each following generation. The ani-
mals have been checked for mortality, feed intake, 
body weight, egg laying intensity and hatchability 
and organ weights. In addition, tissues have been 
tested for the dissemination of transgenic DNA in 
animals that have been fed the diets during up to 
one year. Neither any statistically significant differ-
ences nor any uptake of transgenic DNA from the 
gastrointestinal tract has been observed in these 
animals [Flachowsky et al., 2005].
3.2 Human and primate testing
An experiment involving GM fish with enhanced 
growth characteristics, i.e. GM tilapia expressing 
transgenic tilapia growth hormone, has been 
conducted with human volunteers [Guillen et al., 
1999]. Two groups of 11 healthy volunteers each 
have received diets containing GM or non-GM 
tilapia twice daily for five days. The authors mention 
that the subjects have shown no differences in 
cytological and biochemical composition of blood 
samples taken after termination of the experiment. 
The flavour of the GM tilapia was generally 
perceived as being better than that of non-GM 
tilapia [Guillen et al., 1999]
In addition, in the same study, the transgenic tila-
pia growth hormone expressed in the GM tilapia 
has also been administered intravenously to non-
human primates (i.e. juvenile macaque monkeys) 
daily during 30 days. The macaques have been 
tested for physiological parameters (body weight, 
temperature, heart and breathing rate, body dimen-
sions), blood composition and cytology, and gross 
and microscopic pathology. No effects related to 
the growth hormone administration have been ob-
served [Guillen et al., 1999]. 
3.3 Post-market monitoring  
of allergenic potential
Various studies published in scientific literature fo-
cus on the possible allergenic effects of the market-
approved GM crops. For example, a recently pub-
lished study has verified whether human subjects, 
including allergy patients, from Europe and Korea, 
have developed sera responses to the transgenic 
CP4 EPSPS protein present in GM herbicide-resist-
ant soybean. The underlying premise is that these 
subjects have had a plausible history of exposure to 
GM soybeans given its large-scale production. No 
specific reactions of allergy patients’ sera with CP4 
EPSPS have thus been noted [Hoff et al., 2007].
Sera binding and skin prick tests with extracts 
from GM crops that have been allowed onto the 
European market, and with purified transgenic pro-
teins that occur in these crops, have also been per-
formed in another study. Sera binding has involved 
the use of SDS PAGE followed by immunoblotting. 
No differential effects between extracts of GM and 
non-GM crops have been observed. In addition, no 
sera binding or skin reactions have been observed 
against the transgenic proteins tested [Batista et 
al., 2005]. In another study, sera from soy-allergic 
patients have not shown differential binding to-
wards the individual proteins in GM and non-GM 
soybeans separated by two-dimensional electro-
phoresis [Batista et al., 2007].
The screening for possible sera binding by GM 
maize has also been tested for Starlink™ maize, 
which accidentally has entered into the food sup-
ply in the USA [reviewed by Bucchini and Goldman, 
2002]. Starlink™ maize contains the transgenic Bt 
protein Cry9C, which has become resistant towards 
degradation in insect intestines by one amino acid 
mutation. This stability towards degradation has 
also been observed in systems with pepsin, trypsin, 
and heat. Cry9C also has elicited an allergic serum 
reaction in Brown Norway rats, which are known to 
be IgE-hyperresponders, whilst also another pro-
tein without known allergenic properties tested 
positive in the same test. Based on these consid-
erations, Starlink™ has previously only been al-
lowed onto the market for feed use. Despite this, it 
accidentally has become commingled with human 
food products derived from maize, such as taco 
shells. This has instigated a major recall action and 
a request to consumers to report any allergic reac-
tions that might have been related to the consump-
tion of Starlink™-containing products. These self-
reported cases of allergy have subsequently been 
verified by the American Center for Disease Control 
and Prevention by using sera from these subjects 
for binding tests with Cry9C. This center has been 
unable to confirm allergic reactions to Cry9C based 
on the negative outcomes of these binding tests 
[Sutton et al., 2003].
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An article that has recently been published as the 
outcome of an ILSI Europe activity provides a review 
of the experiences gained with post-market moni-
toring of novel foods [Hepburn et al., 2007]. This 
review highlights various food products that have 
previously undergone post-market monitoring, 
such as the sweetener aspartame, the fat replace-
ment olestra, and the cholesterol-lowering phyto-
sterol esters. In addition, it also highlights the in-
cident involving admixture of Starlink™ maize with 
food, although this cannot be strictly considered a 
post-market monitoring activity (see above).
In case of the sweetener aspartame, the monitor-
ing has included intake surveys in various coun-
tries, after approval of this compound in various 
dry products and carbonated beverages. These 
surveys have shown that the aspartame intake 
is well below the acceptable daily intake for this 
compound. In addition, various effects were relat-
ed by a passive reporting system. These anecdotal 
effects have not been confirmed by follow-up re-
search in animals and humans [reviewed by Hep-
burn et al., 2007].
Olestra is a fat replacement consisting of fatty acid 
esters of sucrose, which are not absorbed after 
consumption from the gastrointestinal tract. For 
olestra, the approaches followed have included 
post-marketing studies on the consumption of 
olestra-containing products including snacks and 
the possible effect on the status of fat-soluble vi-
tamins and carotenoids in consumers in the USA. 
These monitoring activities are to verify pre-mar-
ket assumptions on intake, as well as to verify the 
potential effect on vitamins identified during the 
pre-market assessment. In addition to these moni-
toring activities, also a reporting system for gener-
al passive surveillance has been set up [reviewed 
by Hepburn et al., 2007].
Phytosterol esters have been approved as novel 
foods for the European market under Regulation 
(EC) No 258/97 on ‘Novel Foods’. Their consumption 
can lower the level of serum cholesterol because of 
less cholesterol being taken up from the digesta. 
After market introduction, monitoring has been car-
ried out to verify the assumptions made during the 
pre-market assessment regarding the level of con-
sumption, differentiated over the various consumer 
groups. It has thus been observed by the company 
that the intake is actually lower than initially ex-
pected and that the target population of elderly 
consumers indeed constitutes the main users of 
the phytosterol-containing products, i.e. spread 
(margarine-like). In addition, general surveillance 
has included the registration of complaints through 
a dedicated telephone centre. These complaints 
have subsequently been assessed by health pro-
fessionals, which, however, have not been able to 
specifically link these complaints to phytosterols 
[reviewed by Hepburn et al., 2007].
4 Experiences with health effects of non-GM foods
5 Conclusions
Whilst the internationally harmonised approach 
towards the pre-market safety assessment of 
GMOs can be regarded as rigorous, biotechno-
logical product developers, risk assessors and 
risk managers have to stay alert to new develop-
ments in this area. Various scenarios can be en-
visaged in which the commonly employed safety 
tests are supplemented with additional data dur-
ing the pre-market or post-market assessments. 
The need for such additional tests may arise ei-
ther from additional hazards identified during 
the pre-market assessment, or from uncertainties 
requiring a precautionary approach towards risk 
management. As for the commonly used methods, 
those that have to be applied for the additional 
tests should preferably be appropriate in the con-
text of a regulatory assessment, providing results 
that can withstand scrutiny. In addition, certain 
measures may be facilitated by the current system 
for market approval of GMOs, such as post-market 
monitoring that can draw upon the mandatory la-
belling and traceability of GM foods and feed un-
der Regulation (EC) No 1829/2003.
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The present document is the main output of the ‘In-
ternational workshop on overall approaches to as-
sess and monitor potential short, medium and long 
term effects in relation to consumption of Geneti-
cally Modified Organisms (GMOs) and products de-
rived thereof’ organised by the Joint Research Cen-
tre (JRC) in Ispra (Italy) on 26-27 November 2007.
Experts did not define what is precisely intended 
with ‘short’, ‘medium’ and ‘long term’ health effects. 
Acute effects for instance are certainly ‘short term’ 
and chronic effects (eventually covering the life span 
of an individual) and indirect or delayed effects may 
be considered as ‘longer-term’ effects. It was per-
ceived that such a definition would not contribute to 
this debate since it is acknowledged that the current 
pre-market assessment and post-market monitoring 
cover short term and long term health effects. Like-
wise, the observations made in this document are 
applicable to the three categories.
The workshop represented a key element for the 
accomplishment of component C ‘Health issues in 
relation to GMOs’ of the project proposal ‘Scientific 
and technical contribution to the development of 
an overall health strategy in the area of GMOs’ pre-
sented by the JRC Institute for Health and Consum-
er Protection (IHCP) on request of the Committee 
on Industry, Research and Energy of the European 
Parliament, and approved by the European Parlia-
ment at the end of 20061.
Participants attending the workshop included 22 
experts in different disciplines relevant to pre-as-
sessment and post-marketing evaluation of GMOs 
and GM derived foods/feeds. Experts from the Eu-
ropean Food Safety Authority (EFSA) were closely 
involved in this workshop together with other inter-
nationally acknowledged experts.
The workshop addressed issues raised in a ‘non-
paper’ (see Annex I) that was circulated in advance 
to the participants for their consideration.
1 The Committee on Industry, Research and Energy also 
pointed out the need to study possible health threats 
coming from genetically modified organisms such as 
maize MON863. It also indicated the need for the JRC to 
coordinate research with an overall health strategy.
The observations and recommendations made dur-
ing the two-day discussions have been grouped in 
the present document into four distinct chapters: 
General observations and recommendations, 1. 
Pre-market assessment phase, 2. 
Post-market monitoring phase, 3. 
Future developments and research.4. 
Introduction
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This document focuses on the assessment 1. 
of possible human health effects related to 
the direct consumption of GMOs. In addition, 
when considering ‘animal health’, the empha-
sis is placed on the perspective of humans 
consuming animals fed with GMOs rather 
than animal health per se. In addition, ani-
mals serve also as good indicators for poten-
tial human health problems since their diets 
may contain much higher levels of GMOs than 
humans ever would get.
‘GMOs’ (genetically modified organisms) com-2. 
prise living organisms such as plants, micro-
organisms and animals (as defined in Direc-
tive 2001/18/EC) and food and feed products 
derived thereof [as defined in Regulation (EC) 
No 1829/2003].
From the scientific and food safety point 3. 
of view, GMOs need not necessarily be 
considered as a distinct group with respect 
to potential health effects. With the advent 
of more novel foods, especially functional 
foods, either derived from GMOs or non-
GMOs, the distinction between both will 
become less meaningful.
Food safety concerns products and substanc-4. 
es rather than the technology by which the 
food has been obtained. From there it follows 
that the approaches for pre-market assess-
ment and post-market monitoring of GMOs, 
novel and functional foods (including food 
with health claims), should be coherent. 
An unintended effect, possibly due to the ge-5. 
netic modification process, cannot be known 
or defined a priori, and is thus subject of the 
hazard identification and risk assessment. 
The probability of occurrence of unintended 
effects is part of the uncertainty analysis 
in the risk assessment procedure per se, in 
which the aim is to reach the highest possible 
degree of scientific certainty. 
The distinction between what needs to be 6. 
known for the (safety) evaluation per se and 
what might be scientifically interesting or chal-
lenging to know, but not adding significant in-
formation to the pre-market risk assessment 
or post-market monitoring, should be made. 
The degree of scrutiny should be proportional 
to the magnitude of risk perceived.
‘Health effects of food’ comprises both nega-7. 
tive and positive effects. Benefit analysis 
is nowadays not part of the pre-market risk 
assessment or of the post-market monitor-
ing phase as performed at Community level. 
While zero risk is inexistent in any techno-
logical area, risk-mitigation measures could 
be used to minimise it. Risk-benefit analysis 
will become increasingly important. However, 
safety must continue to be the first priority 
with the highest possible degree of certainty. 
Communication aspects will also have a more 8. 
dominant role; the scientific community and 
the regulators will need to be aware of the new 
types of GMOs being developed. The range 
of organisms modified will certainly become 
much wider than what is currently seen and 
will include an ample array of plant species, 
animals (including fish) and micro-organ-
isms. All experts involved in the pre-market 
assessment and in the post-market monitor-
ing should be proactive and well ahead of the 
state of tools and technologies.
It is highly recommended to establish an inte-9. 
grated stakeholder forum in which the differ-
ent experts/actors (ranging from the technolo-
gy developers, the biotechnology companies, 
breeders, risk assessors, decision makers, 
retailers and other parties contributing to the 
successful and safe introduction of new prod-
ucts) can periodically interact and exchange 
information, in particular in relation to new 
developments, needs, constraints etc. These 
periodic meetings would serve as a dialogue 
forum of experts and would allow the making 
of an adequate inventory of new technologies 
and products, and the monitoring of them. 
The outcome of this dialogue forum would 
also enable proactivity in the anticipation of 
future legislative needs and would further 
contribute to increasing confidence in the ef-
fectiveness of the whole risk assessment and 
management process.
1 General observations
JRC Reference Reports
Overall approaches to assess and monitor potential short, medium and long term effects in relation to consumption  
of Genetically Modified Organisms (GMOs) and products derived thereof
33
As a measure of precaution, a pre-market risk as-
sessment is performed for each individual GMO 
that is ready to enter the market as a commercial 
product. Presently, the comparative approach is 
internationally recognised as the appropriate prin-
ciple for GMO safety assessment. The comparative 
safety assessment (CSA) is based on the compari-
son of a GMO with an appropriate conventional 
counterpart (the comparator) with a history of safe 
use [Kok and Kuiper, 2003]. This allows assessing 
the safety of GMOs relative to products that, even 
if not specifically assessed for safety, are known by 
experience to present no unacceptable health risks, 
under normal conditions of consumption. The com-
parison includes an extensive range of character-
istics, including chemical composition, nutritional 
profile, phenotypic and agronomic characteristics. 
Possible differences between GMOs and their 1. 
appropriate comparators are assessed for 
their safety impact on a case-by-case basis, 
dependent on (1) the specific biological char-
acteristics of that GMO and (2) the intended 
use of that GMO under assessment. 
This approach and the necessary data require-2. 
ment has been established after consensus 
built by various authoritative international 
organisations such as the United Nation Food 
and Agriculture Organisation (FAO), the World 
Health Organisation (WHO) and Organisation 
for Economic Cooperation and Development 
(OECD). International consensus has resulted 
in the publication of guidelines for the safety 
assessment of foods derived from GM plants 
and micro-organisms by Codex Alimentarius 
[Codex Alimentarius, 2003]. These documents 
serve as reference for international trade is-
sues surrounding the safety of foods and 
must be implemented by all Codex members.
In agreement with this international con-3. 
sensus, the European Food Safety Author-
ity (EFSA) has developed GMO guidance 
documents which constitute the basis for 
pre-market GMO risk assessment in the Eu-
ropean Union [EFSA, 2006a]. These docu-
ments, which take into account EC legislation 
and the Codex guidelines, are more detailed 
and provide practical guidance for the com-
pilation of the dossiers and the data require-
ments to be submitted by applicants in the 
frame of regulatory procedures for EU mar-
keting approval of GMOs.
Based on the experience gained so far, the 4. 
comparative approach is considered to be sol-
id and to be the pillar for future developments 
in GMO risk assessment. The weight of evi-
dence based on the currently used toxicologi-
cal, nutritional, molecular, and allergological 
data requirements constitutes a robust frame 
for the prediction of potential health effects. 
The amount of data required for the assess-
ment of GMOs is, in general, much larger 
compared to the data needed for approval of 
conventional or novel foods and it provides a 
sufficient degree of safety assurance. 
The comparative approach implies the com-5. 
parison of the GM under study with respect to 
an appropriate conventional counterpart. The 
selection of this counterpart is considered rel-
atively straightforward for the present gener-
ation of GM plants characterised by a limited 
extent of genetic modifications and with a 
well-known genetic background. In the fu-
ture, GMOs with more complex modifications, 
characterised by more extensive alterations, 
are expected. This may entail a broader se-
lection of appropriate comparators, including 
possibly multiple products with a history of 
safe use, in order to identify possible differ-
ences that may require further investigation.
Extensive similarity exists between safety as-6. 
sessment strategies for GMOs and for novel 
foods (e.g. allergenicity tests, toxicity tests 
with animals, health claims, nutritional as-
sessment, compositional analysis), although 
novel foods assessment may be more chal-
lenging since in some cases a comparator 
with a history of safe use is not available. 
Statistical models and data requirements for 7. 
risk assessment of GM plants and derived 
foods/feeds must be carefully defined up-
front, i.e. as a guide for accurate experimental 
layout and data analysis, to ensure meaning-
ful, reliable and comparable results. This logi-
cal approach allows maximum efficiency/ac-
curacy during data evaluation, and it ensures 
full transparency with respect to uncertainties 
and assumptions of GMO risk assessment. 
When biostatistics are applied a posteriori this 
may lead to unrepresentative conclusions. 
The European Commission and EFSA are im-8. 
plementing since April 2006 an action plan 
2 Pre-market assessment phase
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aiming to improve the support of Member 
States in the authorisation procedure of 
GMOs. Following fruitful discussions with 
EFSA, The Commission will shortly propose 
new detailed rules for the assessment of 
GMOs for food and feed. 
As part of the harmonisation of data require-9. 
ments, for example for the statistical analysis 
applied later, a working group of the EFSA GMO 
Panel is considering an even more objective 
strategy for the identification of biologically 
relevant statistical differences between GMOs 
and their comparators. As briefly described 
above the comparison is made by measuring a 
number of endpoints with the objective of dem-
onstrating biological equivalence of a GMO 
and its control. For each chosen endpoint, or 
for groups of endpoints, limit values for mean-
ingful change have to be set a priori based on 
biological experience and knowledge. When 
this is not feasible, statistical methods can 
be used to calibrate the observed changes 
against background variability observed for 
commercial plant varieties already on the EU 
market and with a history of safe use. 
Within a plant species there is a large natural 10. 
variation (depending on variation of genetic 
background, epigenetics, environmental con-
ditions and developmental conditions) and 
therefore the variability baseline and the link 
to biological relevance of observed statistically 
significant differences between the GM and its 
parental comparator is to be carefully assessed 
on a case-by-case basis, taking into account 
the variation between commercial varieties.
With respect to future developments, it is 11. 
foreseen that, in addition to GM plants in-
tended for food use, new GM plants produc-
ing specific molecules for non-food purposes 
(e.g. pharmaceuticals, vaccines) will be ready 
for marketing. EFSA is currently investigating 
the risk assessment of these new GM plants, 
which should consider incidental exposure of 
consumers in addition to risk management 
focused on containment of these products. In 
anticipation of such, a special guidance docu-
ment for the risk assessment of these prod-
ucts is expected in 2008.
Other developments, driven by industrial in-12. 
novation, include genetically modified micro-
organisms (GMM) and genetically modified 
animals (GMA). For example the first ap-
plication for GM fish is expected in the near 
future. Codex guidance has been developed 
for the risk assessment of edible products 
derived from such animals, while EFSA will 
concentrate on the design of guidance for the 
environmental risk assessment of such GM 
animals. Furthermore EFSA has published a 
guidance document on the safety evaluation 
of GMMs and derived products, which is in 
line with the Codex guidelines [EFSA, 2006b]. 
The EFSA document includes some additional 
environmental aspects, and it focuses par-
ticularly on the risk of gene transfer in the di-
gestive tract, which is recognised as the main 
concern in case of GMMs use in foods. 
The principles for the risk assessment of GM 13. 
plants and GMMs are the same, i.e. the com-
parative safety assessment, and therefore also 
GMMs will be assessed on a case-by-case ba-
sis. The Codex guideline on GMA will be shortly 
formalised, and EFSA is expected to publish a 
pertinent guidance document later on. The EU 
regulatory system may need review and regu-
latory adjustment to accommodate the market-
ing of possible new types of GMMs and GMAs.
As mentioned above, some of the future GMOs 14. 
may contain complex modifications such as 
metabolically engineered and/or nutritionally 
enhanced crops to which a whole new biosyn-
thetic pathway is introduced (e.g. Golden Rice 
with provitamin A containing kernels). In these 
cases, analytical profiling techniques, once 
developed to full robustness and validated, 
may serve as complementary tools to identify 
and characterise any unforeseen metabolic 
perturbations besides those intended.
From a general perspective, the need for test-15. 
ing for potential allergenicity can derive from 
specific hazards identified in the pre-market 
assessment. In addition, this may also address 
the uncertainty remaining over the allergenic 
potential of a product based on the fact that no 
validated models as yet exist for some aspects 
of allergy, including sensitisation of laboratory 
animals. This has to be viewed against the back-
ground of advances in scientific research on the 
mechanisms and diagnosis of allergy, which will 
also have an impact on the detection of poten-
tial allergenic effects of non-GM products.
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Under the current EU GM food and feed 1. 
regulation, it is necessary to introduce, 
where appropriate and on the basis of the 
conclusions of the risk assessment, post-
market monitoring requirements for the use 
of genetically modified foods for human 
consumption and for the use of genetically 
modified feed for animal consumption. 
Post-market monitoring of GM food/feed 2. 
may thus have two aims: (1) confirm the 
assumptions and conclusions of the pre-
market risk assessment, and (2) to identify 
the occurrence of unforeseen health 
effects following consumption of the GMO 
or its derived product. So far, i.e. for the 
GM products currently on the EU market, 
no monitoring of health effects has been 
necessary, but it may be required for those 
cases as outlined by EFSA, namely cases 
that include GM (functional) foods with 
altered nutritional composition and modified 
nutritional value and/or with specific health 
claims. This could be the case for a GM 
food proposed as an alternative or as a 
replacement for a traditional food.
When in certain cases (e.g. products with 3. 
intended positive health effects) during 
the pre-market risk assessment scientific 
evidence is found for a potential negative 
health effect, and when there is uncertainty 
about actual consumption patterns and 
levels of exposure of specific segments of the 
population, or the extent of a potential adverse 
effect linked to the genetic modification, then 
case-specific monitoring should be carried 
out after placing on the market. So far, such a 
situation has not occurred.
For the specific purpose of this study, 4. 
‘monitoring’ is related to the surveillance of 
individuals/groups to observe any possible 
unforeseen health effect. It is carried out on a 
case-by-case basis and its need is identified 
during the process of risk assessment/
management. The working group points out 
that post-market monitoring eventually follows 
a finalised pre-market safety assessment and 
should not (even partly) substitute for it, nor 
should it aim at any further data collection 
which was not available during the pre-market 
safety assessment.
Monitoring needs are defined under Directive 5. 
2001/18/EC and guidance is already available 
but the working group notes that monitoring 
may be necessary for products produced 
from GMO. This may for instance be needed to 
monitor effects on health of products grown 
under contained use conditions (Council 
Directive 90/219/EEC) in greenhouses, stables 
or ponds and not intended for consumption 
(e.g. medicinal plants, GM animals producing 
vaccines, GM fish etc.). It is important to 
point out that monitoring in the context of 
contained use is already carried out, for 
instance in the case of genetically modified 
micro-organisms, and that experience may 
be drawn from this area.
Accurate traceability (which generally is a 6. 
combination of documentation and analyti-
cal testing) of GM food and feed throughout 
the agro-food chain is a prerequisite for sur-
veillance. GMO identification methods are 
based on event-specific identification and 
are available for all EU-approved GMOs al-
though particular technical problems still ex-
ist for distinction between stacked and single 
events in derived products (http://gmo-crl.
jrc.ec.europa.eu/). Accurate traceability also 
comprises the application of robust sampling 
plans. International agreement within Codex 
Alimentarius will facilitate further exchange 
of methods and reference materials for GMO 
identification, in particular for GMOs ap-
proved only outside the EU. 
Efforts are ongoing to develop methods for 7. 
unapproved GMOs. However there is a further 
need for international cooperation and collab-
oration and initiatives should be taken to that 
end. Projects currently ongoing within the Euro-
pean Network of GMO Laboratories may serve 
as a basis for further global partnership. 
Traceability assumes that the GMO genotype 8. 
with respect to the insert is stable through-
out the whole marketing phase. The Working 
Group points out that by all means the occur-
rence of possible false negative results (i.e. a 
test scores negative for GMO presence where-
as in fact GMO is present) must be avoided. 
The Working Group recommends ascertaining 
that the detection method validated for that 
GMO as part of the notification procedure 
must be applicable to the marketed product. 
3 Post-marketing monitoring phase
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The first step in the monitoring of health ef-9. 
fects is the estimation of exposure. Therefore 
the Working Group recommends that when 
monitoring is considered as being required 
under current legislation and according to the 
conclusions obtained during the pre-marketing 
assessment, the identity of the GM should be 
unambiguously known. In addition, this guar-
antees the possibility for a complete withdrawal 
of specific products in cases of safety issues. 
The potential of biomarkers as an aid for esti-10. 
mation of GMO exposure in humans and ani-
mals has been considered. Although this ap-
proach is generally accepted in certain areas 
(e.g. epidemiology of asthma), its applicability 
is considered only for very specific cases, such 
as in nutritionally improved and/or functional 
GM foods, currently not to be addressed.
Exposure assessment requires extensive EU 11. 
consumption data, which are not in all cases 
available and current approaches are based on 
scenarios that assume extensive exposure.
The Working Group has identified the follow-12. 
ing parallels in monitoring needs between GM 
and non-GM crops: 
Especially for foods with specific health 13. 
claims, monitoring is equally important for 
GM as for non-GM foods and specific label-
ling may be required in order to collect data 
on exposure. 
When agricultural products are approved for 14. 
non-food/feed purposes, their accidental 
presence in the food/feed chain may need to 
be traced.
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4 Future developments and research
As indicated in the previous chapters, it is 1. 
foreseen that future GM plant generations will 
contain more complex traits, such as altered 
nutritional profiles, and that a wider range of 
organisms will be used as targets to introduce 
new traits via genetic engineering processes.
Multiple stacked GM varieties obtained by 2. 
conventional breeding, carrying several GM 
traits within the same genome, are already 
on the EU market and are expected to be 
developed increasingly. In this respect EFSA 
has recently issued an opinion on the safety 
assessment of stacked GM plant varieties. 
By default these new traits would not need 
a different risk assessment approach to be 
followed; the comparative safety assessment 
would still be the appropriate principle for 
GMO safety assessment.
New types of GMO events or variety traits 3. 
with specific nutritional and/or health claims 
would need additional basic and fundamental 
research to be conducted also by independent 
publicly funded research institutions/univer-
sities. Such basic research could provide in-
sight into the possible intended and unintend-
ed changes caused by these modifications as 
well as the extent of background variability.
Profiling technologies offering the promise of 4. 
a more accurate picture of the target organ-
ism with respect to integration locus, gene 
function, protein expression and metabolism, 
need to be further validated and tested for 
their application within the framework of a 
comparative safety assessment. In particular, 
bioinformatics tools, already considered as 
an integrative part of the application of these 
technologies, should be further developed, 
as well as the establishment of databases 
containing profiles of products produced un-
der different external conditions and different 
agricultural production practices.
Taking all the aspects above into account, 5. 
cooperation between experts/actors will be-
come increasingly important in the EU and 
pre-market risk assessment and post-market 
monitoring should remain in line with scien-
tifically agreed principles. 
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Executive summary
The Biotechnology & GMOs Unit of the JRC Institute 
for Health and Consumer Protection (IHCP) has de-
veloped a real-time PCR based ready-to-use multi-
target analytical system for the detection of EU 
authorised and unauthorised GM events. The sys-
tem was established upon specific request of the 
European Parliament in the context of the project 
‘Scientific and technical contribution to the devel-
opment of an overall health strategy in the area 
of GMOs’. The approach allows the event-specific 
simultaneous detection of 39 single-insert GMOs, 
comprising all EU approved and all unapproved GM 
events for which a method was submitted to the 
Community Reference Laboratory for GM Food and 
Feed (CRL-GMFF) and stacked events derived from 
them. System performance (specificity, efficiency 
etc) has been successfully confirmed by experi-
mental testing conducted within the CRL-GMFF. The 
project has already been presented to members of 
the European Network of GMO Laboratories (ENGL). 
The ‘real-time PCR based ready-to-use multi-target 
analytical system’ developed by the Biotechnology 
& GMOs Unit, the first analytical tool developed 
worldwide allowing the detection of so many GM 
events simultaneously using event-specific targets, 
could be used to conduct a survey on GMOs pres-
ence on the European territory. 
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1 Introduction 
The project described here has been formulated by 
the Biotechnology & GMOs Unit of the Institute for 
Health and Consumer Protection (Joint Research 
Centre, JRC) in response to component A ‘Routine 
high-throughput for the detection of GMOs’ in the 
context of the project proposal ‘Scientific and tech-
nical contribution to the development of an overall 
health strategy in the area of GMOs’ presented to 
and approved by the European Parliament at the 
beginning of 2007. The project constitutes one of 
the potential analytical alternatives and, by specific 
request of the European Parliament, was aimed at 
developing and providing a fast and handy ready-to-
use multi-target system for the detection of (as many 
as possible) GM events approved and unapproved 
on the European market in a single experiment.
2 Background information and strategy selection
The strategy selected for the realisation of the 
project presented in this document has been for-
mulated and based on a series of considerations 
summarised below.
Over the past years the JRC, through the activities 
conducted by the Biotechnology & GMOs Unit, 
has developed a deep expertise in the different 
analytical aspects involved in quali- and quanti-
tative GMO analysis. The established and recog-
nised leading role in developing, optimising and 
validating analytical tests for the detection, iden-
tification and quantification of GMOs led to the 
establishment, within the Biotechnology & GMOs 
Unit, of the Community Reference Laboratory for 
GM Food and Feed (CRL-GMFF; http://gmo-crl.jrc.
ec.europa.eu/) in the context of Regulation (EC) 
No 1829/2003. 
Principal legal duties and tasks of the CRL-GMFF, as 
defined in Annex I of Regulation (EC) No 1829/2003, 
are: 1) testing and validation of detection methods 
for identification of the transformation event in the 
food or feed and 2) preparation, storage and distri-
bution to national reference laboratories of the ap-
propriate positive and negative control samples. 
Detailed rules for the implementation of Regulation 
(EC) No 1829/2003, and in particular requisites to 
be followed by applicants when submitting a meth-
od of detection to the CRL-GMFF, as specified in An-
nex I of Commission Regulation (EC) No 641/2004, 
include information about the method as such and 
about the method testing carried out by the ap-
plicant and demonstration that the method fulfils, 
among others, the following requirements:
Being event-specific and therefore function-1. 
al only with the GMO or GM based product 
considered (and not functional if applied to 
other events).
Being applicable to samples of the food or 2. 
feed, to the control samples and to the refer-
ence material. 
Regulation (EC) No 1829/2003 also defines label-
ling requirements for both food and feed (Articles 
12 and 24, respectively) establishing a threshold of 
0.9%, calculated at the single ingredient level, for 
the adventitious or technically unavoidable pres-
ence of authorised GMOs, and it therefore com-
bines – from the applicant point of view – the need 
of providing an event-specific method as prerequi-
site for approval, with the need of quantification. 
Since the introduction of mandatory labelling re-
quirements in 1997 [Regulation (EC) No 258/97] dif-
ferent analytical approaches have been developed 
for the purpose of GM quantification: among all 
alternatives tested, real-time PCR [Holland et al., 
1991] turned out to be the most successful, accu-
rate and powerful technique for nucleic acid quan-
tification and, accordingly, it is now the method of 
choice in the EU and worldwide for GM quantifica-
tion [Miraglia et al., 2004].
In line with what is indicated above, all methods 
submitted by applicants to the CRL-GMFF for valida-
tion are, so far, also meant for quantitative purpos-
es and are based on the real-time PCR technique. 
Real-time PCR is a modification of the traditional 
polymerase chain reaction technique that incorpo-
rates the ability to directly measure and quantify 
the reaction while amplification is taking place. 
Among the different chemistries developed for the 
purpose, the most widely used in GMO quantifica-
tion is the TaqMan® approach [Heid et al., 1996]. 
The chemistry is the key to the detection system 
(Fig. 1). A labelled probe (i.e. TaqMan®) designed 
to anneal to the target sequence between the 
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traditional forward and reverse primers, in addition 
to adding specificity to the reaction, produces a flu-
orescent signal that is proportional to the amount 
of PCR product being amplified.
The TaqMan® probe is labelled at the 5’ end with 
a reporter fluorochrome (R) and with a quencher 
fluorochrome (Q) at the 3’ end. As long as both 
fluorochromes are in proximity, the quencher mol-
ecule stops all fluorescence by the reporter. How-
ever, as Taq polymerase extends the primer, the 
intrinsic 5’ to 3’ nuclease activity of Taq degrades 
the probe, releasing the reporter fluorochrome. 
The amount of fluorescence released during the 
amplification phase is proportional to the amount 
of product generated in each cycle. The detection 
system is so sensitive that fewer than 10 copies of 
target DNA can be detected.
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Whereas the wide diffusion and adoption of the 
real-time PCR approach relies on its reliability for 
DNA quantification, the technique is also more 
and more frequently used for end point analysis, 
for qualitative detection purposes, thanks to its 
increased intrinsic specificity and to the fact that 
it allows straight extrapolation of results directly 
from the instrument software avoiding analysis of 
PCR products by gel electrophoresis, a step that 
represents the main risk in terms of laboratory con-
tamination [Reiting et al., 2007]. 
As requested by the European Parliament, the 
project had the purpose of developing a fast and 
ready-to-use system for the detection of approved 
and unapproved GM events. 
In the formulation of the project strategy all el-
ements indicated above were considered and 
combined: 
Analytical target(s): the approach is based on 
the detection of the different GM events by 
using event-specific methods. According to the 
mandate of Regulation (EC) No 1829/2003, the 
CRL-GMFF has a strategic comparative advantage, 
in that it is the first point of delivery, within the 
EU, of the information related to the molecular 
data of approved GMOs and in particular of the 
GMOs that, most probably already approved or 
commercialised elsewhere, are intended to be 
placed on the EU market. At the time of project 
formulation, the CRL-GMFF had received for 
validation dossiers containing molecular data 
and event-specific methods for the detection of 
39 individual GM events (without considering 21 
dossiers provided for the validation of methods 
for stacked GM lines) in 7 plant species (http://
gmo-crl.jrc.ec.europa.eu/statusofdoss.htm).
Figure 1. TaqMan® principle in real-time PCR. 1) Forward 
and reverse primers are extended by the Taq polymerase 
as in a traditional PCR reaction. A probe with two fluores-
cent dyes attached anneals to the target DNA sequence 
between the two primers. (2) As the Taq polymerase 
extends the primer, the probe is displaced. (3) The 5’ nu-
clease activity of Taq polymerase cleaves the reporter dye 
from the probe. (4) After release of the reporter dye (R) 
from the quencher (Q), a fluorescent signal is generated.
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Maize Oilseed rape Cotton Soybean Rice Sugar beet Potato 
Bt11 T45 MON1445 A2704-12 LLRICE62 H7-1 EH92-527-1
NK603 Ms8 MON88913 40-3-2 LLRice601
GA21 Rf3 LLCotton25 MON89788 Bt63 Rice
MON863 GT73 MON 531 DP-356043
1507 Rf1 MON15985 
T25 Rf2 281-24-236 X 
59122 Ms1 3006-210-23
MON810 Topas 19/2
MIR604
Bt176
MON88017
LY038
3272
MON89034
Bt10
Table 1. List of targets detected by the system. In addition to the 39 individual GM events included in the table, the system 
allows the detection of all stacked events derived from them, in 7 plant species. 
Methodological choice: the approach is based on 
real-time PCR. Indeed, real-time PCR, in addition to 
the intrinsic specificity mentioned above, has the 
advantage of being a technique already commonly 
diffused in the EU and worldwide and adopted by 
most if not all EU control laboratories. This choice 
guarantees the possibility of immediate use and in-
tegration in the laboratories working routine, with-
out the need of acquisition of new instrumentation 
or of implementation of new procedures. 
Format strategy: the format selected is in line 
with the aim of the project, i.e. to provide a rapid 
multi-target system (allowing the simultaneous 
detection of all targets in a single experiment) in 
a ready-to-use format, therefore reducing to the 
minimum the laboratory handling steps. The real-
time PCR system will be delivered in the format 
of pre-spotted plates containing, in lyophilized 
format, all primers and probes for the individual 
detection of all 39 single-insert GM events (includ-
ing both approved and non-approved) for which a 
method has been submitted to the CRL-GMFF, and 
of the corresponding 7 plants species (maize, cot-
ton, rice, oilseed rape, soybean, sugar beet, and 
potato) (Table 1). To use system the operator would 
just need to perform a few simple steps: extract 
the DNA from the sample, mix it with the provided 
Universal PCR Master Mix, load the mixture on the 
plate, and start the time temperature programme. 
Results would then be extrapolated directly from 
the ad hoc computer software. 
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The ultimate deliverable of the project, by the end 
of 2007, is the production, testing, and evalua-
tion of pre-spotted real-time PCR plates suitable 
for the event–specific detection of 39 GM events, 
approved and unapproved in the EU, and of the 
corresponding 7 plant species. An additional de-
liverable planned is their distribution to European 
control laboratories, members of the European 
Network of GMO Laboratories (ENGL), for ad-
ditional testing. The project, as formulated, in-
cludes the production of a total amount of 1000 
pre-spotted plates so distributed: 1) production 
of 50 pre-spotted plates as first delivery, intend-
ed for preliminary testing and verification of the 
functionality of the system and 2) production of 
remaining 950 plates for final method perform-
ance verification, distribution to ENGL laborato-
ries and conduction of the survey. 
Below, phases and milestones of the project: 
Project strategy formulation (January 2007)1. 
Data collection and verification (February/2. 
March 2007)
Method definition (March/May 2007) 3. 
Delivery of methods information and result of 4. 
analytical evaluation (May 2007)
Customisation of the 96-wells plates for pre-5. 
spotting of all 48 assays (June 2007)
Production of positive and negative DNA sam-6. 
ples (June – August 2007) 
Production and delivery (July 2007) of the first 7. 
set of pre-spotted plates (No 50) for in-house 
testing
Intermediate reporting to the European Par-8. 
liament (July 2007)
In-house testing (September – October 2007)9. 
Method performance evaluation (November 10. 
2007)
Confirmation of suitability of experimental 11. 
conditions and order confirmation for the pro-
duction of the remaining 950 plates (Novem-
ber 2007)
Project and product presentation to ENGL lab-12. 
oratories (November 2007)
Distribution of plates to ENGL control labora-13. 
tories for testing (Beginning 2008)
Data collection, obtained for ENGL laboratories 14. 
participating in the testing phase and evalua-
tion and assessment reporting (End 2008)
3 Timeline, milestones and deliverables
JRC Reference Reports
Development of a real-time PCR based ready-to-use multi-target analytical system for the detection of EU authorised and unauthorised GM events
46
Project strategy formulation.1.  The project 
strategy has been elaborated and formulated 
as indicated above. Practical implementation 
of the project implied the outsourced probes 
and primers synthesis and robotised spot-
ting phases. Assessment of commercial com-
panies providing this service was limited by 
the fact that some of the methods included 
the use of TaqMan® MGB probes, produced 
and distributed exclusively by the company 
Applied Biosystems. During this phase sev-
eral meetings were held with experts of the 
company Applied Biosystems to discuss and 
clarify the different technical aspects of the 
project, in particular the ones related to meth-
od optimisation, robotised plate spotting, and 
confidentiality of data. 
Data collection and verification. 2. Molecular 
data (primers and probes sequences) of all 
methods submitted to the CRL-GMFF for the 
detection of single-insert GM events were 
retrieved from the Central Core Sequence 
Database of the Biotechnology & GMOs Unit, 
compared and manually verified with original 
dossiers submitted by applicants. Since for 
the detection of stacked GM lines applicants 
are required to submit one event-specific 
method for each parental GM event compos-
ing the stacked line, all stacked events, ex-
cept one (cotton 281-24-236 X 3006-210-23) 
were already represented in the list of single 
insert events. A total of 41 different methods 
were selected (= all methods submitted to the 
CRL-GMFF for method validation represented 
once, including methods for emergency cas-
es, e.g. Bt10 maize and LL601 rice) for the de-
tection of a total of 39 GM events. This step 
included the ad hoc design of a real-time PCR 
method specific for Bt10 maize, the only event 
for which a quantitative method was not avail-
able. Primers and probes sequences are avail-
able upon request and according to confiden-
tiality agreement respecting the mandate of 
the CRL-GMFF.
Method definition. 3. The detection of all events 
in a single experiment (i.e. in the same plate) 
implies that all methods work and perform 
satisfactorily under the same experimental 
and cycling conditions. Evaluation of experi-
mental compatibilities / incompatibilities 
among methods included primers and probes 
compositions, relative Tm and working 
concentration, PCR thermal protocols, reac-
tion volumes and input DNA amounts.
The following are the common compatible experi-
mental conditions selected: 
Individual reaction volume: 50 μl  ✓
Primers and probes working concentrations:  ✓
(900 nM Primers/250 nM Probes) 
Input DNA/reaction: 100 ng ✓
Reaction buffer:   ✓
AB TaqMan® Universal PCR Master Mix
Plate set-up: row based (Figure 2) including  ✓
48 assays. Each plate will enable the opera-
tor to analyse 2 samples in single replicate 
(or 1 sample in duplicate) with each assay.
Cycling conditions:  ✓
Step Stage T°C
Time 
(sec)
Acqui-
sition
Cy-
cles
1
Initial 
denaturation
95°C 600 No 1
Denaturation 95°C 15 No
2 Annealing & 
Extension
60°C 60 Yes 45
4 Report of activities and experimental testing 
Methods’ details and consolidated experi-4. 
mental conditions were delivered at the end 
of May 2007 to the company Applied Bio-
systems (Applied Biosystems, Foster City, 
US) with confirmation of order for an initial 
amount of 50 pre-spotted plates intended 
for preliminary testing and verification of the 
functionality of the system. 
Production of this initial amount of pre-spotted 5. 
plates was preceded by the customisation and 
verification of the robotised system for the pre-
spotting of 48 assays on 96-wells plates to 
guarantee absence of plate to plate variability. 
Production of positive and negative DNA sam-6. 
ples: Assay testing required the availability of 
DNA samples for all GM events included in the 
study and for the 7 wild type plants species. 
Large scale DNA extraction from the 7 wild type 
plants species started in June 2007. Required 
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amounts were calculated according to the de-
fined experimental design including verifica-
tion of method efficiency, specificity, and LOD 
calculation for all assays analysed individually. 
Wild type plants species DNA was required both 
as negative control and as diluent to bring each 
GM event to the same GM % while guarantee-
ing the same amount of input DNA in each test. 
DNA from each plant species was extracted fol-
lowing the validated DNA extraction method for 
that species or applying the CTAB method [Mur-
ray et al., 1980]. DNA extraction was followed 
by DNA concentration estimation by spectro-
photometry and fluorimetry (Picogreen®) and 
inhibition test [Zel et al., 2008] to assess DNA 
quality, absence of inhibitory compounds and 
optimal working concentration. 
Extraction of DNA from all 39 GM events was 
conducted during the months of July and Au-
gust 2007 using the same approach used 
for the wt using the corresponding validated 
methods. Positive control samples are avail-
able at the CRL-GMFF either as 100% pure 
GM material (flour), as purified GM DNA, or 
as 1% w/w food/feed sample. Accordingly, to 
standardise testing conditions for all assays, 
the highest GM concentration examined was 
1% from which sequential dilutions were per-
formed to estimate assays LOD. 
The first set of 50 pre-spotted plates for in-7. 
house testing was delivered in July 2007.
As from project proposal timeline, an interme-8. 
diate report containing structure and status 
of advancement of the project was delivered 
to the European Parliament in July 2007. 
In-house testing:9.  Verification of performance 
of the real-time PCR based ready-to-use ana-
lytical system included the following: 
Confirmation of robotised spotting quali-• 
ty i.e. for all the 48 assays the same qual-
ity and quantity of primers and probes 
was delivered in each well of the plate 
with no cross contamination between ad-
jacent wells
Verification of method performance, i.e. • 
the specificity, reliability and efficiency 
was maintained for all methods, i.e. all 
methods were performing satisfactorily 
using the unique experimental conditions 
defined for the pre-spotted plates and no 
significant method performance deviation 
occurred in comparison with original vali-
dated conditions. 
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Figure 2. Plate set-up
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Confirmation of specificity for each in-• 
dividual method. As specified in An-
nex I of Commission Regulation (EC) No 
641/2004 each method submitted to the 
CRL-GMFF must be pre-validated by the 
notifier and it must meet defined per-
formance criteria including test of spe-
cificity. In practice the fact that differ-
ent methods are submitted by different 
notifiers and the differential develop-
ment and submission times (spread over 
years) leads to the fact that that none of 
the methods submitted to the CRL-GMFF, 
and included in the present project, was 
tested for specificity against the whole 
range of GM events.
For experimental testing, individual GM DNA 
samples were diluted to working concentra-
tion in wild type DNA of the corresponding 
plant species to guarantee the same amount 
of DNA present in each plate well.
Individual samples for specificity tests were 
prepared as follows:
WT•  = 20 ng/μl WT DNA solutions from 
each plant species. 5 μl/well (=100 ng to-
tal) loaded in each well.
GM•  = WT and GM DNA stock solutions 
were used to prepare individual GM sam-
ples at 0.1% GM content (20 ng/μl). Each 
event (100 ng total DNA at 0.1% in 5 μl) 
was loaded in each well.
Amplification reaction mixture in the final • 
volume per reaction well:
Component Final con-centration
µl/
reaction
TaqMan® Universal PCR 
Master Mix (2x) 1x 25
Nuclease free water # 20
Template DNA (100 ng at 
20 ng/μl) # 5.0
Total reaction volume: 50 
Specificity of the system, and of each of the 
48 methods included in the plate, was as-
sessed by testing each wt plant species and 
each GM event individually against the whole 
set of methods at the cycling conditions indi-
cated above. 
In cases of doubtful results (false positives, 
contamination etc), tests were repeated, spe-
cifically for the method under evaluation, on 
normal RT-PCR plates under original method’s 
validation conditions and under pre-spotted 
plates conditions.
LOD: System LOD will be defined on final 
batch of plates prior to distribution to ENGL 
laboratories. Preliminary sensitivity testing 
was performed by individually loading, in 
each well, according to the plate design, the 
corresponding DNA (GM or wt) sample in a fi-
nal quantity of 100 ng/well.
The highest concentration tested was 0.1% 
w/w from which sequential dilutions have 
been performed. Lowest GM% tested so far 
0.045%.
Absolute copy numbers equivalents detect-
ed in the different plant species (Table 2) 
were calculated for each event according to 
the nuclear content (average C1 value) of the 
individual plant species (Table 3) by dividing 
the sample DNA weight by the published av-
erage C1 value for the genome of the corre-
sponding species. 
Results obtained from the preliminary sen-
sitivity testing are reported in Table 4. Data, 
reported as average Cts, are based on four 
repetitions. The four repetitions always fell 
within 1 Ct value.
The system was also tested with composite 
samples resembling real samples to be includ-
ed in the survey to verify correspondence of 
results. Two examples are reported:
Sample 1: Test material GeM MU01 (GM events 
in Mixed Flours) from GeMMA Proficiency 
Scheme. As from Proficiency Scheme report, 
the sample was known to be: Positive for 
Roundup Ready soybean (not quantified but 
reported to be < 0.72% w/w), MON810 maize 
(1.29% w/w) and NK603 maize (1.33% w/w) 
and negative for Bt176 maize, Bt11 maize, GA21 
maize, TC1507 maize and MON863 maize.
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Common name
Total amount of 
DNA in reaction 
(ng/5 µl)
Species copy 
numbers GM copies (0.1%)*
GM copies 
(0.045%)*
Maize 100 36.697 36 16.5 
Cotton 100 42.918 42 19
Rice 100 222.222 222 100
Oilseed rape 100 86.956 86 39
Soybean 100 88.495 88 39.8
Sugar beet 100 80.000 80 36
Potato 100 55.555 55 25
Table 2. Copy numbers equivalents detected for the 7 plant 
species. 
Scientific name Common name C1 average value
Zea mays Maize 2.725 pg
Gossypium hirsutum (2n=4X) Cotton 2.33 pg
Oryza sativa ssp Rice 0.45 pg
Brassica napus Oilseed rape 1.15 pg
Glycine max (2n=4X) Soybean 1.13 pg
Beta vulgaris ssp. saccharifera Sugar beet 1.25 pg
Solanum tuberosum (2n=4X) Potato 1.8 pg
Table 3. Nuclear DNA content of plant species included in the 
project (Arumuganathan and Earle, 1991). 
* GM copy numbers calculated assuming homozygous 
status for all GM events 
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Qualitative results obtained with the pre-spot-
ted plates matched at 100% with Proficiency 
Scheme test report.
Sample 2: Test material C4.4 (GM in corn flour) 
from FAPAS Proficiency Scheme. As from Profi-
ciency Scheme report, the sample was known 
to be: Positive for MON810 maize (0.4%), GA21 
maize (1.5%), Bt176 maize (0.8%), Bt11 (3.0%), 
Herculex (59122) maize (1.0%) and MON863 
maize (1.5%) and negative for T25 maize, 
CBH351 maize and NK603 maize. Qualitative 
results obtained with the pre-spotted plates 
matched with Proficiency Scheme test report; 
in addition results indicated a minute contami-
nation (Ct ~ 42-43) from GT73 oilseed rape, not 
tested during the Proficiency Scheme.
Upon evaluation of the results and verification 10. 
of the suitability of experimental conditions, 
order confirmation was given to the company 
Applied Biosystems for the production of the 
remaining 950 plates (November 2007)
The formulation of the ‘real-time PCR based 11. 
ready-to-use multi-target analytical system’ 
and the results so far obtained on system per-
formance were presented in November 2007 at 
the Plenary Meeting of the ENGL. ENGL experts 
evaluated very positively both the system and 
the shown performance, and approximately 50 
laboratories indicated their interest in further 
testing the system.
Distribution of plates to ENGL control laborato-12. 
ries for testing was conducted at the beginning 
of 2008 upon receipt of the remaining 950 pre-
spotted plates and batch LOD definition.
The present report is prepared in fulfilment of 13. 
timelines requirements, established within the 
project ‘Scientific and technical contribution to 
the development of an overall health strategy 
in the area of GMOs’. It is anticipated that an 
additional reporting will follow including as-
sessment of presence of authorised and unau-
thorised GM events in the European market. 
Method average Ct
HGM Maize R 23.596
Bt11 42.115
NK603 38.669
GA21 (method 1) 37.949
GA21 (method 2) 36.504
MON863 36.447
1507 36.467
T25 32.056
59122 36.970
MON810 37.333
MIR604 32.628
Bt176 34.626
MON88017 36.441
LY038 37.328
3272 36.203
MON89034 36.720
Bt10 38.611
Lectin Soybean R 21.337
A2704-12 33.683
40-3-2 35.235
MON89788 33.616
DP-356043 34.446
UGPase Potato R 16.372
EH92-527-1 33.473
CruA Oilseed R 23.020
T45 34.730
Ms8 37.014
Rf3 37.076
GT73 (RT63) 34.574
Rf1 34.814
Rf2 33.809
Ms1 36.314
Topas 19/2 36.604
PLD Rice R 21.170
LLRICE62 33.795
LLRice601 32.416
Bt63 34.711
Rice P35S::bar 35.714
GS Sugar beet R 21.954
H7-1 36.037
SAH7 Cotton R 27.359
MON1445 38.263
MON88913 39.267
LLCotton25 40.776
MON 531 40.995
281-24-236 39.048
3006-210-23 39.766
Table 4. Average Ct values for each method based on 4 repeti-
tions. Input DNA = 100 ng/well. GM% = 0.045% (w/w).  
The four repetitions always fell within 1 Ct value.
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5 Conclusions
Experimental data as illustrated in the previous 
section, indicate that the ‘real-time PCR based 
ready-to-use multi-target analytical system’ de-
veloped by the Biotechnology & GMOs Unit in the 
context of the project ‘Scientific and technical con-
tribution to the development of an overall health 
strategy in the area of GMOs’ presented to and ap-
proved by the European Parliament early 2007 is fit 
for the purpose of detection of several GM events in 
a single experiment and, according to the purpose 
of the project, is a very useful tool for the conduc-
tion of a survey of the presence on the European 
market of authorised and unauthorised GM events. 
The system was developed to allow the simultane-
ous event-specific detection of 39 GM events be-
longing to 7 plant species and of the corresponding 
species-specific genes. Specificity of each of the 
methods (Figure 3) was confirmed and sensibility 
of the system allows the detection of even minute 
amounts of GMOs. The methodology and format 
selected allow the immediate implementation of 
the system since real-time PCR using the 96-well 
plates format is a technique commonly diffused in 
the EU and worldwide and adopted by most if not 
all EU control laboratories.
The system offers the unique opportunity to al-
low testing for all 39 events with minor handling 
required. Using the traditional approach, a series 
of sequential tests need to be performed on each 
sample to be analysed. Screening tests, based on 
the detection of the 35S promoter and the NOS 
terminator (regulatory sequences globally used in 
building GMOs), are generally applied at first to as-
say, irrespective of modification type, the presence 
of a GMO. Depending on the outcome of the 35S/
NOS results, additional tests are performed for 
confirmation and identification purposes. Event-
specific methods, the only ones allowing the univo-
cal identification of each GM event, need so far to 
be performed one at the time. 
Accordingly, testing for the presence of several 
GMOs in the same sample results in a huge amount 
of work, making it almost impossible for control 
laboratories to test each food/feed sample for all 
events. In contrast, by using the system just pre-
sented, the user would just need to perform a few 
simple steps: extract the DNA from the sample, 
mix it with the provided Universal PCR Master Mix, 
load the mixture on the plate and start the time 
temperature programme. Straight and immediate 
extrapolation of the results directly from the ad 
hoc instrument software imparts additional value 
to the system. A few examples are reported below, 
showing how results are visualised (Figures 4-7).
The developed system has the additional advan-
tage of guaranteeing comparable results since 
plates are pre-developed and pre-tested to guaran-
tee absence of plate to plate variability within the 
same batch. 
This is an additional step towards harmonisation: 
The implementation of the ready-to-use sys-• 
tem as described above will be a major step 
towards harmonisation throughout the Euro-
pean Community. 
The flexibility of the system allows the rapid • 
inclusion of new methods targeting GM events 
for which a method becomes available.
If all control laboratories use this system, • 
results will be comparable between the labo-
ratories. Double-checking of samples can be 
avoided.
The laboratories will save time and reduce • 
costs, because several individual steps are 
eliminated when using the system.
Since only one source (e.g. JRC) for the deliv-• 
erable of the ready-to-use system would be 
considered, laboratories don’t need to test 
the reliability of the components individually.
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Figure 3. Summary of results from specificity tests performed on each method included in the system. Columns correspond to 
methods, and rows to individual samples. Green dots indicate correct result; orange dots indicate unexpected result (i.e. method 
unspecificity or contamination of the sample). As shown, only results related to three method/sample combinations do not cor-
respond to expectation. In those cases confirmation was not possible due to unavailability of certified controls.
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Figure 4. Detection of potato event EH92-527-1. A. Interpretation of the results from the table: well A7 corresponds to the potato reference 
gene method while well B9 corresponds to the EH92-527-1 event-specific method. B. Graphic representation of results: curves above the 
threshold line (red horizontal line) indicate positive reaction for potato reference gene and for event EH92-527-1. 
A B
W ell S am ple Nam e Detector  Nam e R eporter C t
1 HMG FAM-TAMRA FAM Undetermined
2 Cotton FAM-TAMRA FAM Undetermined
3 Rice FAM-TAMRA FAM Undetermined
4 OSR FAM-TAMRA FAM Undetermined
5 Soya FAM-TAMRA FAM Undetermined
6 SB FAM-TAMRA FAM Undetermined
7 Potato FAM-TAMRA FAM 17.1273
8 Bt11 FAM-TAMRA FAM Undetermined
9 NK603 FAM-TAMRA FAM Undetermined
10 GA21 FAM-TAMRA FAM Undetermined
11 MON863 FAM-TAMRA FAM Undetermined
12 1507 FAM-TAMRA FAM Undetermined
13 T25 FAM-TAMRA FAM Undetermined
14 59122 FAM-TAMRA FAM Undetermined
15 H7-1 FAM-TAMRA FAM Undetermined
16 MON810 FAM-TAMRA FAM Undetermined
17 281 FAM-TAMRA FAM Undetermined
18 3006 FAM-TAMRA FAM Undetermined
19 LL62 FAM-TAMRA FAM Undetermined
20 T45 FAM-TAMRA FAM Undetermined
21 EH-92 FAM-TAMRA FAM 32.70036
22 Ms8 FAM-TAMRA FAM Undetermined
23 Rf3 FAM-TAMRA FAM Undetermined
24 GT73 FAM-TAMRA FAM Undetermined
25 LL25 FAM-TAMRA FAM Undetermined
26 531 FAM-TAMRA FAM Undetermined
27 A2704 FAM-TAMRA FAM Undetermined
28 MIR604 FAM-TAMRA FAM Undetermined
29 Rf1 FAM-TAMRA FAM Undetermined
30 Rf2 FAM-TAMRA FAM Undetermined
31 Ms1 FAM-TAMRA FAM Undetermined
32 Topas FAM-TAMRA FAM Undetermined
33 1445 FAM-TAMRA FAM Undetermined
34 Bt176 FAM-TAMRA FAM Undetermined
35 15985 FAM-TAMRA FAM Undetermined
36 40-3-2 FAM-TAMRA FAM Undetermined
37 GA21 syn FAM-TAMRA FAM Undetermined
38 88017 FAM-TAMRA FAM Undetermined
39 LY038 FAM-TAMRA FAM Undetermined
40 3272 FAM-TAMRA FAM Undetermined
41 89788 FAM-TAMRA FAM Undetermined
42 89034 FAM-TAMRA FAM Undetermined
43 DP-3560 FAM-TAMRA FAM Undetermined
44 88913 FAM-TAMRA FAM Undetermined
45 P35:BAR FAM-TAMRA FAM Undetermined
46 LL601 FAM-TAMRA FAM Undetermined
47 Bt63 FAM-TAMRA FAM Undetermined
48 Bt10 FAM-TAMRA FAM Undetermined
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A B
W ell S am ple Nam e Detector  Nam e R eporter C t
1 HMG FAM-TAMRA FAM Undetermined
2 Cotton FAM-TAMRA FAM Undetermined
3 Rice FAM-TAMRA FAM Undetermined
4 OSR FAM-TAMRA FAM Undetermined
5 Soya FAM-TAMRA FAM Undetermined
6 SB FAM-TAMRA FAM 23.41622
7 Potato FAM-TAMRA FAM Undetermined
8 Bt11 FAM-TAMRA FAM Undetermined
9 NK603 FAM-TAMRA FAM Undetermined
10 GA21 FAM-TAMRA FAM Undetermined
11 MON863 FAM-TAMRA FAM Undetermined
12 1507 FAM-TAMRA FAM Undetermined
13 T25 FAM-TAMRA FAM Undetermined
14 59122 FAM-TAMRA FAM Undetermined
15 H7-1 FAM-TAMRA FAM 35.46205
16 MON810 FAM-TAMRA FAM Undetermined
17 281 FAM-TAMRA FAM Undetermined
18 3006 FAM-TAMRA FAM Undetermined
19 LL62 FAM-TAMRA FAM Undetermined
20 T45 FAM-TAMRA FAM Undetermined
21 EH-92 FAM-TAMRA FAM Undetermined
22 Ms8 FAM-TAMRA FAM Undetermined
23 Rf3 FAM-TAMRA FAM Undetermined
24 GT73 FAM-TAMRA FAM Undetermined
25 LL25 FAM-TAMRA FAM Undetermined
26 531 FAM-TAMRA FAM Undetermined
27 A2704 FAM-TAMRA FAM Undetermined
28 MIR604 FAM-TAMRA FAM Undetermined
29 Rf1 FAM-TAMRA FAM Undetermined
30 Rf2 FAM-TAMRA FAM Undetermined
31 Ms1 FAM-TAMRA FAM Undetermined
32 Topas FAM-TAMRA FAM Undetermined
33 1445 FAM-TAMRA FAM Undetermined
34 Bt176 FAM-TAMRA FAM Undetermined
35 15985 FAM-TAMRA FAM Undetermined
36 40-3-2 FAM-TAMRA FAM Undetermined
37 GA21 syn FAM-TAMRA FAM Undetermined
38 88017 FAM-TAMRA FAM Undetermined
39 LY038 FAM-TAMRA FAM Undetermined
40 3272 FAM-TAMRA FAM Undetermined
41 89788 FAM-TAMRA FAM Undetermined
42 89034 FAM-TAMRA FAM Undetermined
43 DP-3560 FAM-TAMRA FAM Undetermined
44 88913 FAM-TAMRA FAM Undetermined
45 P35:BAR FAM-TAMRA FAM Undetermined
46 LL601 FAM-TAMRA FAM Undetermined
47 Bt63 FAM-TAMRA FAM Undetermined
48 Bt10 FAM-TAMRA FAM Undetermined
Figure 5. Detection of sugar beet event H7-1. A. Interpretation of the results from the table: well E6 corresponds to the sugar beet 
reference gene method while well F3 corresponds to the H7-1 event-specific method. B. Graphic representation of results: curves 
above the threshold line (red horizontal line) indicate positive reaction for sugar beet reference gene and for event H7-1. 
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Figure 6. Detection of cotton event MON15985. A. Interpretation of the results from the table: well E2 corresponds to the SAH7 cotton 
reference gene method, wells G2 and G11 correspond to the MON531 and MON15985 event-specific methods, respectively. B. Graphic 
representation of results: curves above the threshold line (red horizontal line) indicate positive reaction for SAH7 cotton reference gene and 
for events MON531 and MON15985.
W ell S ample N ame D etec to r N ame R epo rter C t
1 HMG FAM-TAMRA FAM Undetermined
2 Cotton FAM-TAMRA FAM 25.41579
3 Rice FAM-TAMRA FAM Undetermined
4 OSR FAM-TAMRA FAM Undetermined
5 Soya FAM-TAMRA FAM Undetermined
6 SB FAM-TAMRA FAM Undetermined
7 Potato FAM-TAMRA FAM Undetermined
8 Bt11 FAM-TAMRA FAM Undetermined
9 NK603 FAM-TAMRA FAM Undetermined
10 GA21 FAM-TAMRA FAM Undetermined
11 MON863 FAM-TAMRA FAM Undetermined
12 1507 FAM-TAMRA FAM Undetermined
13 T25 FAM-TAMRA FAM Undetermined
14 59122 FAM-TAMRA FAM Undetermined
15 H7-1 FAM-TAMRA FAM Undetermined
16 MON810 FAM-TAMRA FAM Undetermined
17 281 FAM-TAMRA FAM Undetermined
18 3006 FAM-TAMRA FAM Undetermined
19 LL62 FAM-TAMRA FAM Undetermined
20 T45 FAM-TAMRA FAM Undetermined
21 EH-92 FAM-TAMRA FAM Undetermined
22 Ms8 FAM-TAMRA FAM Undetermined
23 Rf3 FAM-TAMRA FAM Undetermined
24 GT73 FAM-TAMRA FAM Undetermined
25 LL25 FAM-TAMRA FAM Undetermined
26 531 FAM-TAMRA FAM 37.62348
27 A2704 FAM-TAMRA FAM Undetermined
28 MIR604 FAM-TAMRA FAM Undetermined
29 Rf1 FAM-TAMRA FAM Undetermined
30 Rf2 FAM-TAMRA FAM Undetermined
31 Ms1 FAM-TAMRA FAM Undetermined
32 Topas FAM-TAMRA FAM Undetermined
33 1445 FAM-TAMRA FAM Undetermined
34 Bt176 FAM-TAMRA FAM Undetermined
35 15985 FAM-TAMRA FAM 35.40573
36 40-3-2 FAM-TAMRA FAM Undetermined
37 GA21 syn FAM-TAMRA FAM Undetermined
38 88017 FAM-TAMRA FAM Undetermined
39 LY038 FAM-TAMRA FAM Undetermined
40 3272 FAM-TAMRA FAM Undetermined
41 89788 FAM-TAMRA FAM Undetermined
42 89034 FAM-TAMRA FAM Undetermined
43 DP-3560 FAM-TAMRA FAM Undetermined
44 88913 FAM-TAMRA FAM Undetermined
45 P35:BAR FAM-TAMRA FAM Undetermined
46 LL601 FAM-TAMRA FAM Undetermined
47 Bt63 FAM-TAMRA FAM Undetermined
48 Bt10 FAM-TAMRA FAM Undetermined
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W ell S am ple Nam e Detector  Nam e R eporter C t
1 HMG FAM-TAMRA FAM 24.1
2 Cotton FAM-TAMRA FAM Undetermined
3 Rice FAM-TAMRA FAM Undetermined
4 OSR FAM-TAMRA FAM Undetermined
5 Soya FAM-TAMRA FAM Undetermined
6 SB FAM-TAMRA FAM Undetermined
7 Potato FAM-TAMRA FAM Undetermined
8 Bt11 FAM-TAMRA FAM Undetermined
9 NK603 FAM-TAMRA FAM Undetermined
10 GA21 FAM-TAMRA FAM Undetermined
11 MON863 FAM-TAMRA FAM Undetermined
12 1507 FAM-TAMRA FAM Undetermined
13 T25 FAM-TAMRA FAM Undetermined
14 59122 FAM-TAMRA FAM Undetermined
15 H7-1 FAM-TAMRA FAM Undetermined
16 MON810 FAM-TAMRA FAM Undetermined
17 281 FAM-TAMRA FAM Undetermined
18 3006 FAM-TAMRA FAM Undetermined
19 LL62 FAM-TAMRA FAM Undetermined
20 T45 FAM-TAMRA FAM Undetermined
21 EH-92 FAM-TAMRA FAM Undetermined
22 Ms8 FAM-TAMRA FAM Undetermined
23 Rf3 FAM-TAMRA FAM Undetermined
24 GT73 FAM-TAMRA FAM Undetermined
25 LL25 FAM-TAMRA FAM Undetermined
26 531 FAM-TAMRA FAM Undetermined
27 A2704 FAM-TAMRA FAM Undetermined
28 MIR604 FAM-TAMRA FAM Undetermined
29 Rf1 FAM-TAMRA FAM Undetermined
30 Rf2 FAM-TAMRA FAM Undetermined
31 Ms1 FAM-TAMRA FAM Undetermined
32 Topas FAM-TAMRA FAM Undetermined
33 1445 FAM-TAMRA FAM Undetermined
34 Bt176 FAM-TAMRA FAM Undetermined
35 15985 FAM-TAMRA FAM Undetermined
36 40-3-2 FAM-TAMRA FAM Undetermined
37 GA21 syn FAM-TAMRA FAM Undetermined
38 88017 FAM-TAMRA FAM Undetermined
39 LY038 FAM-TAMRA FAM Undetermined
40 3272 FAM-TAMRA FAM Undetermined
41 89788 FAM-TAMRA FAM Undetermined
42 89034 FAM-TAMRA FAM Undetermined
43 DP-3560 FAM-TAMRA FAM Undetermined
44 88913 FAM-TAMRA FAM Undetermined
45 P35:BAR FAM-TAMRA FAM Undetermined
46 LL601 FAM-TAMRA FAM Undetermined
47 Bt63 FAM-TAMRA FAM Undetermined
48 Bt10 FAM-TAMRA FAM 35.53
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Figure 7. Detection of unapproved maize event Bt10. Event-specific detection. A. Interpretation of the results from the table: well 
A1 corresponds to the maize reference gene method while well D12 corresponds to the Bt10 event-specific method. B. Graphic 
representation of results: curves above the threshold line (green horizontal line) indicate positive reaction for maize reference 
gene and for event Bt10. 
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